

# PA NT COOPERATION TREAT

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 13 July 2001 (13.07.01)	
International application No. PCT/US00/14471	Applicant's or agent's file reference ISPH-0459
International filing date (day/month/year) 25 May 2000 (25.05.00)	Priority date (day/month/year) 04 June 1999 (04.06.99)
<b>Applicant</b> BENNETT, C., Frank et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

27 December 2000 (27.12.00)


in a notice effecting later election filed with the International Bureau on:

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer H. Zhou
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



## PCT COOPERATION TREATY

PCT  
NOTIFICATION OF ELECTION  
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

Date of mailing (day/month/year) 13 July 2001 (13.07.01)	To:  Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No. PCT/US00/14471	Applicant's or agent's file reference ISPH-0459
International filing date (day/month/year) 25 May 2000 (25.05.00)	Priority date (day/month/year) 04 June 1999 (04.06.99)
Applicant  BENNETT, C., Frank et al	

1. The designated Office is hereby notified of its election made:

 in the demand filed with the International Preliminary Examining Authority on:

27 December 2000 (27.12.00)

 in a notice effecting later election filed with the International Bureau on:2. The election  was was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  H. Zhou
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:  
JANE MASSEY LICATA  
LAW OFFICES OF JANE MASSEY LICATA  
66 E. MAIN STREET  
MARLTON, NJ 08053

NOV 18 2001

PCT

NOTIFICATION OF TRANSMITTAL OF  
INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing  
(day/month/year)

09 NOV 2001

Applicant's or agent's file reference

IMPORTANT NOTIFICATION

ISPH-0459

International application No.

International filing date (day/month/year)

Priority date (day/month/year)

PCT/US00/14471

25 May 2000 (25.05.2000)

04 June 1999 (04.06.1999)

Applicant

ISIS PHARMACEUTICALS, INC.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US	Authorized Officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Thomas G. Larson Telephone No. (703) 308-0196

Form PCT/IPEA/416 (July 1992)



## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

## (PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>ISPH-0459</b>	FOR FURTHER ACTION <span style="float: right;">See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)</span>	
International application No. <b>PCT/US00/14471</b>	International filing date (day/month/year) <b>25 May 2000 (25.05.2000)</b>	Priority date (day/month/year) <b>04 June 1999 (04.06.1999)</b>
International Patent Classification (IPC) or national classification and IPC <b>IPC(7): A61K 31/70; C07H 21/00; C12N 5/06 and US Cl.: 435/375; 514/44; 536/24.5</b>		
Applicant <b>ISIS PHARMACEUTICALS, INC.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 3 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 11 sheets.

3. This report contains indications relating to the following items:

- I  Basis of the report
- II  Priority
- III  Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV  Lack of unity of invention
- V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI  Certain documents cited
- VII  Certain defects in the international application
- VIII  Certain observations on the international application

Date of submission of the demand <b>27 December 2000 (27.12.2000)</b>	Date of completion of this report <b>14 September 2001 (14.09.2001)</b>
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <b>Thomas G. Larson, Ph.D.</b> 
Facsimile No. (703)305-3230	Telephone No. (703) 308-0196



## I. Basis of the report

## 1. With regard to the elements of the international application:\*

 the international application as originally filed. the description:pages 1-105 as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the claims:pages NONE, as originally filedpages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages 106-108/6, filed with the letter of 14 SEPTEMBER 2001 the drawings:pages 1-10, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the sequence listing part of the description:pages 1-40, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

the language of publication of the international application (under Rule 48.3(b)).

the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

 contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4.  The amendments have resulted in the cancellation of: the description, pages NONE the claims, Nos. NONE the drawings, sheets/fig NONE5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.



**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)

Claims 1-60 \_\_\_\_\_ YES  
Claims NONE \_\_\_\_\_ NO

Inventive Step (IS)

Claims 1-60 \_\_\_\_\_ YES  
Claims NONE \_\_\_\_\_ NO

Industrial Applicability (IA)

Claims 1-60 \_\_\_\_\_ YES  
Claims NONE \_\_\_\_\_ NO**2. CITATIONS AND EXPLANATIONS**

Claims 1-60 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest antisense oligonucleotides targeted to the 5' untranslated or 3' untranslated regions, or nucleotides 334-469 or 552-1153 of the human B7-1 transcript, or methods of using these antisense oligonucleotides to inhibit expression of human B7-1.

----- NEW CITATIONS -----



10

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number  
WO 00/74687 A1

(51) International Patent Classification<sup>6</sup>: A61K 31/70, G. [US/US]; 1159 Montura Road, San Marcos, CA 92069  
C07H 21/00, C12N 5/06 (US).

(21) International Application Number: PCT/US00/14471

(74) Agents: LICATA, Jane, Massey et al.; Law Offices of  
Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053  
(US).

(22) International Filing Date: 25 May 2000 (25.05.2000)

(25) Filing Language:

English

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language:

English

(30) Priority Data:

09/326,186 4 June 1999 (04.06.1999) US

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 09/326,186 (CIP)  
Filed on 4 June 1999 (04.06.1999)

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1

(54) Title: ANTISENSE MODULATION OF B7 PROTEIN EXPRESSION

WO 00/74687 A1  
(57) Abstract: Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.




## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/14471

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC(6) : A61K 31/70; C07H 21/00; C12N 5/06 US CL : 435/375; 514/44; 536/24.5		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91.31, 375, 514/44; 536/24.31, 24.5		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,077,833 A (BENNETT et al.) 20 June 2000, see entire document.	1-8, 10, and 12-30
X	US 5,942,607 A (FREEMAN et al.) 24 August 1999, see column 3, line 61, to column 4, line 15; column 14, lines 30-37; and column 17, line 59, to column 18, line 50, especially column 18, lines 34-50.	1, 2, 8, 10, 12, 16-21, 24-28
---		13-15, 22, 23, 29, and 30
Y		1-5, 8, 10, and 12-30
X	US 5,877,021 A (STINCHCOMB et al.) 02 March 1999, see column 5, line 66, to column 6, line 23; column 7, line 26, to column 8, line 60; column 10, line 15 to column 12, line 45; and column 15, lines 36-37.	6, 7
---		1, 8, 10, 16, 17, 24, 27
Y		1-6, 8, 10, and 12-30
X	US 5,667,998 A (DOUGHERTY et al.) 16 September 1997, see column 24, line 35, to column 27, line 27.	
X	WO 96/18736 (RIBOZYME PHARMACEUTICALS) 20 June 1996, see page 19, line 25, to page 20, line 2; page 33, line 10, to page 36, line 16; page 37, line 20, to page 41, line 4; and page 45, line 3, to page 56, line 26.	
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		
<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search 20 July 2000 (20.07.2000)		Date of mailing of the international search report 14 AUG 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer Thomas C. Collier, Ph.D. Telephone No. (703) 308-0196



**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US00/14471

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.: 9 and 11  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Please See Continuation Sheet
  
3.  Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.



**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US00/14471

**Continuation of Box I Reason 2:** because the computer readable format of the sequence listing for this application is defective. Claims 9 and 11 recite specific SEQ. ID. NOS. that could not be searched other than by a sequence search. Therefore, these claims are unsearchable.

**Continuation of B. FIELDS SEARCHED Item 3:** USPT, DWPI, EPAB, and JPAB, all using WEST; BIOSIS, CAPLUS, and MEDLINE, all using STN. Search Terms: B7, B7-1, B7-2, antisense, anti sense, ribozyme, oligonucleotide, inflammatory, autoimmune, rheumatoid arthritis, psoriasis, multiple sclerosis



09/980,953

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number  
WO 00/074687 A1

(51) International Patent Classification\*: A61K 31/70, C07H 21/00, C12N 5/06 (74) Agents: LICATA, Jane, Massey et al.: Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).

(21) International Application Number: PCT/US00/14471 (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, IJU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, L, C, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 25 May 2000 (25.05.2000) (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/326,186 4 June 1999 (04.06.1999) US (Published: — with international search report)

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US 09/326,186 (CIP) Filed on 4 June 1999 (04.06.1999) (48) Date of publication of this corrected version: 4 July 2002

(71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]: 2292 Faraday Avenue, Carlsbad, CA 92008 (US).


(72) Inventors; and (15) Information about Correction:  
(75) Inventors/Applicants (for US only): BENNETT, C., Frank [US/US]: 1347 Cassins Street, Carlsbad, CA 92008 (US). VICKERS, Timothy, A. [US/US]: 253 Luiseno Avenue, Oceanside, CA 92057 (US). KARRAS, James, G. [US/US]: 1159 Montura Road, San Marcos, CA 92069 (US). see PCT Gazette No. 27/2002 of 4 July 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/074687 A1

(54) Title: ANTISENSE MODULATION OF B7 PROTEIN EXPRESSION

(57) Abstract: Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.



## ANTISENSE MODULATION OF B7 PROTEIN EXPRESSION

## CROSS-REFERENCE TO RELATED APPLICATIONS

5 This is a continuation-in-part of U.S. Application Serial No. 09/326,186, filed June 4, 1999, which is a continuation-in-part of U.S. Application Serial No. 08/777,266, filed December 31, 1996.

## FIELD OF THE INVENTION

10 This invention relates to diagnostics, research reagents and therapeutics for disease states which respond to modulation of T cell activation. In particular, this invention relates to antisense oligonucleotide interactions with certain messenger ribonucleic acids (mRNAs) or DNAs 15 involved in the synthesis of proteins that modulate T cell activation. Antisense oligonucleotides designed to hybridize to nucleic acids encoding B7 proteins are provided. These oligonucleotides have been found to lead to the modulation of the activity of the RNA or DNA, and 20 thus to the modulation of T cell activation. Palliative, therapeutic and prophylactic effects result.

## BACKGROUND OF THE INVENTION

Inflammation is a localized protective response mounted by tissues in response to injury, infection, or 25 tissue destruction resulting in the destruction of the infectious or injurious agent and isolation of the injured tissue. A typical inflammatory response proceeds as follows: recognition of an antigen as foreign or recognition of tissue damage, synthesis and release of 30 soluble inflammatory mediators, recruitment of inflammatory cells to the site of infection or tissue damage, destruction and removal of the invading organism or damaged tissue, and deactivation of the system once the invading organism or damage has been resolved. In many human

-2-

diseases with an inflammatory component, the normal, homeostatic mechanisms which attenuate the inflammatory responses are defective, resulting in damage and destruction of normal tissue.

5       Cell-cell interactions are involved in the activation of the immune response at each of the stages described above. One of the earliest detectable events in a normal inflammatory response is adhesion of leukocytes to the vascular endothelium, followed by migration of leukocytes  
10 out of the vasculature to the site of infection or injury. In general, the first inflammatory cells to appear at the site of inflammation are neutrophils, followed by monocytes and lymphocytes. Cell-cell interactions are also critical for activation of both B-lymphocytes (B cells) and T-  
15 lymphocytes (T cells) with resulting enhanced humoral and cellular immune responses, respectively.

The hallmark of the immune system is its ability to distinguish between self (host) and nonself (foreign invaders). This remarkable specificity exhibited by the  
20 immune system is mediated primarily by T cells. T cells participate in the host's defense against infection but also mediate organ damage of transplanted tissues and contribute to cell attack in graft-versus-host disease (GVHD) and some autoimmune diseases. In order to induce an  
25 antigen-specific immune response, a T cell must receive signals delivered by an antigen-presenting cell (APC). T cell-APC interactions can be divided into three stages: cellular adhesion, T cell receptor (TCR) recognition, and costimulation. At least two discrete signals are required  
30 from an APC for induction of T cell activation. The first signal is antigen-specific and is provided when the TCR interacts with an antigen in the context of a major histocompatibility complex (MHC) protein, or an MHC-related  
35 CD1 protein, expressed on the surface of an APC ("CD," standing for "cluster of differentiation," is a term used

to denote different T cell surface molecules). The second (costimulatory) signal involves the interaction of the T cell surface antigen, CD28, with its ligand on the APC, which is a member of the B7 family of proteins.

5 CD28, a disulfide-linked homodimer of a 44 kilodalton polypeptide and a member of the immunoglobulin superfamily, is one of the major costimulatory signal receptors on the surface of a resting T cell for T cell activation and cytokine production (Allison, *Curr. Opin. Immunol.*, 1994, 6, 414; Linsley and Ledbetter, *Annu. Rev. Immunol.*, 1993, 11, 191; June et al., *Immunol. Today*, 1994, 15, 321). Signal transduction through CD28 acts synergistically with TCR signal transduction to augment both interleukin-2 (IL-2) production and proliferation of naive T cells. B7-1 (also known as CD80) was the first ligand identified for CD28 (Liu and Linsley, *Curr. Opin. Immunol.*, 1992, 4, 265). B7-1 is normally expressed at low levels on APCs, however, it is upregulated following activation by cytokines or ligation of cell surface molecules such as CD40 (Lenschow et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1993, 90, 11054; Nabavi et al., *Nature*, 1992, 360, 266). Initial studies suggested that B7-1 was the CD28 ligand that mediated costimulation (Reiser et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1992, 89, 271; Wu et al., *J. Exp. Med.*, 1993, 178, 1789; Harlan et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1994, 91, 3137). However, the subsequent demonstration that anti-B7-1 monoclonal antibodies (mAbs) had minimal effects on primary mixed lymphocyte reactions and that B7-1-deficient mice responded normally to antigens (Lenschow et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1993, 90, 11054; Freeman et al., *Science*, 1993, 262, 909) resulted in the discovery of a second ligand for the CD28 receptor, B7-2 (also known as CD86). In contrast with anti-B7-1 mAbs, anti-B7-2 mAbs are potent inhibitors of T cell

-4-

proliferation and cytokine production (Wu et al., *J. Exp. Med.*, 1993, 178, 1789; Chen et al., *J. Immunol.*, 1994, 152, 2105; Lenschow et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1993, 90, 11054). B7:CD28 signaling may be a necessary component 5 of other T cell costimulatory pathways, such as CD40:CD40L (CD40 ligand) signaling (Yang et al., *Science*, 1996, 273, 1862).

In addition to binding CD28, B7-1 and B7-2 bind the cytolytic T-lymphocyte associated protein CTLA4. CTLA4 is 10 a protein that is structurally related to CD28 but is expressed on T cells only after activation (Linsley et al., *J. Exp. Med.*, 1991, 174, 561). A soluble recombinant form of CTLA4, CTLA4-Ig, has been determined to be a more efficient inhibitor of the B7:CD28 interaction than 15 monoclonal antibodies directed against CD28 or a B7 protein. *In vivo* treatment with CTLA4-Ig results in the inhibition of antibody formation to sheep red blood cells or soluble antigen (Linsley et al., *Science*, 1992, 257, 792), prolongation of cardiac allograft and pancreatic 20 islet xenograft survival (Lin et al., *J. Exp. Med.*, 1993, 178, 1801; Lenschow et al., 1992, *Science*, 257, 789; Lenschow et al., *Curr. Opin. Immunol.*, 1991, 9, 243), and significant suppression of immune responses in GVHD (Hakim et al., *J. Immun.*, 1995, 155, 1760). It has been proposed 25 that CD28 and CTLA4, although both acting through common B7 receptors, serve opposing costimulatory and inhibitory functions, respectively (Allison et al., *Science*, 1995, 270, 932). CTLA4Ig, which binds both B7-1 and B7-2 molecules on antigen-presenting cells, has been shown to 30 block T-cell costimulation in patients with stable psoriasis vulgaris, and to cause a 50% or greater sustained improvement in clinical disease activity in 46% of the patients to which it was administered. This result was

-5-

dose-dependent. Abrams et al., *J. Clin. Invest.*, 1999, 9, 1243-1225.

European Patent Application No. EP 0 600 591, published June 8, 1994 (A2), discloses a method of 5 inhibiting tumor cell growth in which tumor cells from a patient are recombinantly engineered *ex vivo* to express a B7-1 protein and then reintroduced into a patient. As a result, an immunologic response is stimulated against both B7-transfected and nontransfected tumor cells.

10 International Publication No. WO 95/03408, published February 2, 1995, discloses nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation, including B7-2 proteins. Also disclosed are antibodies to B7-2 proteins and methods of producing B7-2 proteins.

15 International Publication No. WO 95/05464, published February 23, 1995, discloses a polypeptide, other than B7-1, that binds to CTLA4, CD28 or CTLA4-Ig. Also disclosed are methods for obtaining a nucleic acid encoding such a polypeptide.

20 International Publication No. WO 95/06738, published March 9, 1995, discloses nucleic acids encoding B7-2 (also known as B70) proteins. Also disclosed are antibodies to B7-2 proteins and methods of producing B7-2 proteins.

European Patent Application No. EP 0 643 077, 25 published March 15, 1995 (A1), discloses a monoclonal antibody which specifically binds a B7-2 (also known as B70) protein. Also disclosed are methods of producing monoclonal antibodies which specifically bind a B7-2 protein.

30 U.S. Patent No. 5,434,131, issued July 18, 1995, discloses the CTLA4 protein as a ligand for B7 proteins. Also disclosed are methods of producing CTLA4 fusion proteins (e.g., CTLA4-Ig) and methods of regulating immune responses using antibodies to B7 proteins or CTLA4 35 proteins.

-6-

International Publication No. WO 95/22619, published August 24, 1995, discloses antibodies specific to B7-1 proteins which do not bind to B7-2 proteins. Also disclosed are methods of regulating immune responses using 5 antibodies to B7-1 proteins.

International Publication No. WO 95/34320, published December 21, 1995, discloses methods for inhibiting T cell responses using a first agent which inhibits a costimulatory agent, such as an CTLA4-Ig fusion protein, 10 and a second agent which inhibits cellular adhesion, such as an anti-LFA-1 antibody. Such methods are indicated to be particularly useful for inhibiting the rejection of transplanted tissues or organs.

International Publication No. WO 95/32734, published 15 December 7, 1995, discloses Fc $\gamma$ RII bridging agents which either prevent the upregulation of B7 molecules or impair the expression of ICAM-3 on antigen presenting cells. Such Fc $\gamma$ RII bridging agents include proteins such as aggregated human IgG molecules or aggregated Fc fragments of human IgG 20 molecules.

International Publication No. WO 96/11279, published April 18, 1996 (A2) and May 17, 1996 (A3), discloses recombinant viruses comprising genetic sequences encoding (1) one or more immunostimulatory agents, including B7-1 25 and B7-2, and (2) antigens from a disease causing agent. Also disclosed are methods of treating diseases using such recombinant viruses.

To date, there are no known therapeutic agents which effectively regulate and prevent the expression of B7 30 proteins such as B7-1 and B7-2. Thus, there is a long-felt need for compounds and methods which effectively modulate critical costimulatory molecules such as the B7 proteins. It is anticipated that oligonucleotides capable of 35 modulating the expression of B7 proteins provide for a novel therapeutic class of anti-inflammatory agents with

activity towards a variety of inflammatory or autoimmune diseases, or disorders or diseases with an inflammatory component such as asthma, juvenile diabetes mellitus, myasthenia gravis, Graves' disease, rheumatoid arthritis, 5 allograft rejection, inflammatory bowel disease, multiple sclerosis, psoriasis, lupus erythematosus, systemic lupus erythematosus, diabetes, multiple sclerosis, contact dermatitis, rhinitis and various allergies. In addition, oligonucleotides capable of modulating the expression of B7 10 proteins would provide a novel means of manipulating the *ex vivo* proliferation of T cells.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, oligonucleotides are provided which specifically hybridize 15 with nucleic acids encoding B7-1 or B7-2. Certain oligonucleotides of the invention are designed to bind either directly to mRNA transcribed from, or to a selected DNA portion of, the B7-1 or B7-2 gene, thereby modulating the amount of protein translated from a B7-1 or B7-2 mRNA 20 or the amount of mRNA transcribed from a B7-1 or B7-2 gene, respectively.

Oligonucleotides may comprise nucleotide sequences sufficient in identity and number to effect specific hybridization with a particular nucleic acid. Such 25 oligonucleotides are commonly described as "antisense." Antisense oligonucleotides are commonly used as research reagents, diagnostic aids, and therapeutic agents.

It has been discovered that the B7-1 and B7-2 genes, encoding B7-1 and B7-2 proteins, respectively, are 30 ~~particularly amenable to this approach. As a consequence~~ of the association between B7 expression and T cell activation and proliferation, inhibition of the expression of B7-1 or B7-2 leads to inhibition of the synthesis of B7-1 or B7-2, respectively, and thereby inhibition of T cell 35 activation and proliferation. Additionally, the

oligonucleotides of the invention may be used to inhibit the expression of one of several alternatively spliced mRNAs of a B7 transcript, resulting in the enhanced expression of other alternatively spliced B7 mRNAs. Such 5 modulation is desirable for treating various inflammatory or autoimmune disorders or diseases, or disorders or diseases with an inflammatory component such as asthma, juvenile diabetes mellitus, myasthenia gravis, Graves' disease, rheumatoid arthritis, allograft rejection, 10 inflammatory bowel disease, multiple sclerosis, psoriasis, lupus erythematosus, systemic lupus erythematosus, diabetes, multiple sclerosis, contact dermatitis, rhinitis, various allergies, and cancers and their metastases. Such modulation is further desirable for preventing or 15 modulating the development of such diseases or disorders in an animal suspected of being, or known to be, prone to such diseases or disorders. The invention also relates to pharmaceutical compositions which comprise an antisense oligonucleotide to a B7 protein in combination with a 20 second anti-inflammatory agent, such as a second antisense oligonucleotide to a protein which mediates intercellular interactions, e.g., an intercellular adhesion molecule (ICAM) protein.

Methods comprising contacting animals with 25 oligonucleotides specifically hybridizable with nucleic acids encoding B7 proteins are herein provided. These methods are useful as tools, for example, in the detection and determination of the role of B7 protein expression in various cell functions and physiological processes and 30 conditions, and for the diagnosis of conditions associated with such expression. Such methods can be used to detect the expression of B7 genes (i.e., B7-1 or B7-2) and are thus believed to be useful both therapeutically and diagnostically. Methods of modulating the expression of B7 35 proteins comprising contacting animals with

-9-

oligonucleotides specifically hybridizable with a B7 gene are herein provided. These methods are believed to be useful both therapeutically and diagnostically as a consequence of the association between B7 expression and T cell activation and proliferation. The present invention 5 also comprises methods of inhibiting B7-associated activation of T cells using the oligonucleotides of the invention. Methods of treating conditions in which abnormal or excessive T cell activation and proliferation 10 occurs are also provided. These methods employ the oligonucleotides of the invention and are believed to be useful both therapeutically and as clinical research and diagnostic tools. The oligonucleotides of the present invention may also be used for research purposes. Thus, 15 the specific hybridization exhibited by the oligonucleotides of the present invention may be used for assays, purifications, cellular product preparations and in other methodologies which may be appreciated by persons of ordinary skill in the art.

20 The methods disclosed herein are also useful, for example, as clinical research tools in the detection and determination of the role of *B7-1* or *B7-2* expression in various immune system functions and physiological processes and conditions, and for the diagnosis of conditions 25 associated with their expression. The specific hybridization exhibited by the oligonucleotides of the present invention may be used for assays, purifications, cellular product preparations and in other methodologies which may be appreciated by persons of ordinary skill in the art. For example, because the oligonucleotides of this 30 invention specifically hybridize to nucleic acids encoding B7 proteins, sandwich and other assays can easily be constructed to exploit this fact. Detection of specific hybridization of an oligonucleotide of the invention with a 35 nucleic acid encoding a B7 protein present in a sample can

-10-

routinely be accomplished. Such detection may include detectably labeling an oligonucleotide of the invention by enzyme conjugation, radiolabeling or any other suitable detection system. A number of assays may be formulated 5 employing the present invention, which assays will commonly comprise contacting a tissue or cell sample with a detectably labeled oligonucleotide of the present invention under conditions selected to permit hybridization and measuring such hybridization by detection of the label, as 10 is appreciated by those of ordinary skill in the art.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a bar graph showing the inhibitory effect of the indicated oligonucleotides on B7-1 protein expression in COS-7 cells.

15 Figure 2 is a dose-response curve showing the inhibitory effect of oligonucleotides on cell surface expression of B7-1 protein. Solid line, ISIS 13812; dashed line, ISIS 13800; dotted line, ISIS 13805.

Figure 3 is a bar graph showing the inhibitory effect 20 of the indicated oligonucleotides on cell surface expression of B7-2 in COS-7 cells.

Figure 4 is a bar graph showing the inhibitory effect of the indicated oligonucleotides, including ISIS 10373 (a 20-mer) and ISIS 10996 (a 15-mer) on cell surface 25 expression of B7-2 in COS-7 cells.

Figure 5 is a bar graph showing the specificity of inhibition of B7-1 or B7-2 protein expression by oligonucleotides. Cross-hatched bars, B7-1 levels; striped bars, B7-2 levels.

30 Figure 6 is a dose-response curve showing the inhibitory effect of oligonucleotides having antisense sequences to ICAM-1 (ISIS 2302) or B7-2 (ISIS 10373) on cell surface expression of the ICAM-1 and B7-2 proteins. Solid line with X's, levels of B7-1 protein on cells 35 treated with ISIS 10373; dashed line with asterisks, levels

-11-

of ICAM-1 protein on cells treated with ISIS 10373; solid line with triangles, levels of B7-1 protein on cells treated with ISIS 2302; solid line with squares, levels of ICAM-1 protein on cells treated with ISIS 10373.

5 Figure 7 is a bar graph showing the effect of the indicated oligonucleotides on T cell proliferation.

Figure 8 is a dose-response curve showing the inhibitory effect of oligonucleotides on murine B7-2 protein expression in COS-7 cells. Solid line with 10 asterisks, ISIS 11696; dashed line with triangles, ISIS 11866.

Figure 9 is a bar graph showing the effect of oligonucleotides ISIS 11696 and ISIS 11866 on cell surface expression of murine B7-2 protein in IC-21 cells. Left 15 (black) bars, no oligonucleotide; middle bars, 3  $\mu$ M indicated oligonucleotide; right bars, 10  $\mu$ M indicated oligonucleotide.

Figure 10 is a graph showing the effect of ISIS 17456 on severity of EAE at various doses.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligonucleotides for use in antisense inhibition of the function of RNA and DNA encoding B7 proteins including B7-1 and B7-2. The present invention also employs oligonucleotides which are designed 25 to be specifically hybridizable to DNA or messenger RNA (mRNA) encoding such proteins and ultimately to modulate the amount of such proteins transcribed from their respective genes. Such hybridization with mRNA interferes with the normal role of mRNA and causes a modulation of its 30 function in cells. The functions of mRNA to be interfered with include all vital functions such as translocation of the RNA to the site for protein translation, actual translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and possibly even 35 independent catalytic activity which may be engaged in by

-12-

the RNA. The overall effect of such interference with mRNA function is modulation of the expression of a B7 protein, wherein "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a B7 5 protein. In the context of the present invention, inhibition is the preferred form of modulation of gene expression.

Oligonucleotides may comprise nucleotide sequences sufficient in identity and number to effect specific 10 hybridization with a particular nucleic acid. Such oligonucleotides which specifically hybridize to a portion of the sense strand of a gene are commonly described as "antisense." Antisense oligonucleotides are commonly used as research reagents, diagnostic aids, and therapeutic 15 agents. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes, for example to distinguish between the functions of various members of a biological 20 pathway. This specific inhibitory effect has, therefore, been harnessed by those skilled in the art for research uses.

The specificity and sensitivity of oligonucleotides is also harnessed by those of skill in the art for therapeutic 25 uses. For example, the following U.S. patents demonstrate palliative, therapeutic and other methods utilizing antisense oligonucleotides. U.S. Patent 5,135,917 provides antisense oligonucleotides that inhibit human interleukin-1 receptor expression. U.S. Patent 5,098,890 30 is directed to antisense oligonucleotides complementary to the c-myb oncogene and antisense oligonucleotide therapies for certain cancerous conditions. U.S. Patent 5,087,617 provides methods for treating cancer patients with antisense oligonucleotides. U.S. Patent 5,166,195 provides 35 oligonucleotide inhibitors of HIV. U.S. Patent 5,004,810

-13-

provides oligomers capable of hybridizing to herpes simplex virus Vmw65 mRNA and inhibiting replication. U.S. Patent 5,194,428 provides antisense oligonucleotides having antiviral activity against influenza virus. U.S. Patent 5 4,806,463 provides antisense oligonucleotides and methods using them to inhibit HTLV-III replication. U.S. Patent 5,286,717 provides oligonucleotides having a complementary base sequence to a portion of an oncogene. U.S. Patent 5,276,019 and U.S. Patent 5,264,423 are directed to 10 phosphorothioate oligonucleotide analogs used to prevent replication of foreign nucleic acids in cells. U.S. Patent 4,689,320 is directed to antisense oligonucleotides as antiviral agents specific to CMV. U.S. Patent 5,098,890 provides oligonucleotides complementary to at least a 15 portion of the mRNA transcript of the human c-myb gene. U.S. Patent 5,242,906 provides antisense oligonucleotides useful in the treatment of latent EBV infections.

It is preferred to target specific genes for antisense attack. "Targeting" an oligonucleotide to the associated 20 nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is 25 associated with a particular disorder or disease state, or a foreign nucleic acid from an infectious agent. In the present invention, the target is a cellular gene associated with several immune system disorders and diseases (such as inflammation and autoimmune diseases), as well as with 30 ostensibly "normal" immune reactions (such as a host animal's rejection of transplanted tissue), for which modulation is desired in certain instances. The targeting process also includes determination of a region (or regions) within this gene for the oligonucleotide 35 interaction to occur such that the desired effect, either

-14-

detection or modulation of expression of the protein, will result. Once the target region have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently 5 well and with sufficient specificity to give the desired effect.

Generally, there are five regions of a gene that may be targeted for antisense modulation: the 5' untranslated region (hereinafter, the "5'-UTR"), the translation 10 initiation codon region (hereinafter, the "tIR"), the open reading frame (hereinafter, the "ORF"), the translation termination codon region (hereinafter, the "tTR") and the 3' untranslated region (hereinafter, the "3'-UTR"). As is known in the art, these regions are arranged in a typical 15 messenger RNA molecule in the following order (left to right, 5' to 3'): 5'-UTR, tIR, ORF, tTR, 3'-UTR. As is known in the art, although some eukaryotic transcripts are directly translated, many ORFs contain one or more sequences, known as "introns," which are excised from a 20 transcript before it is translated; the expressed (unexcised) portions of the ORF are referred to as "exons" (Alberts et al., *Molecular Biology of the Cell*, 1983, Garland Publishing Inc., New York, pp. 411-415). Furthermore, because many eukaryotic ORFs are a thousand 25 nucleotides or more in length, it is often convenient to subdivide the ORF into, e.g., the 5' ORF region, the central ORF region, and the 3' ORF region. In some instances, an ORF contains one or more sites that may be targeted due to some functional significance *in vivo*. 30 Examples of the latter types of sites include intragenic stem-loop structures (see, e.g., U.S. Patent No. 5,512,438) and, in unprocessed mRNA molecules, intron/exon splice sites. Within the context of the present invention, one preferred intragenic site is the region encompassing the 35 translation initiation codon of the open reading frame

-15-

(ORF) of the gene. Because, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon." A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Furthermore, 5'-UUU functions as a translation initiation codon *in vitro* (Brigstock et al., *Growth Factors*, 1990, 4, 45; Gelbert et al., *Somat. Cell. Mol. Genet.*, 1990, 16, 173; Gold and Stormo, in: *Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology*, Vol. 2, 1987, Neidhardt et al., eds., American Society for Microbiology, Washington, D.C., p. 1303). Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions, in order to generate related polypeptides having different amino terminal sequences (Markussen et al., *Development*, 1995, 121, 3723; Gao et al., *Cancer Res.*, 1995, 55, 743; McDermott et al., *Gene*, 1992, 117, 193; Perri et al., *J. Biol. Chem.*, 1991, 266, 12536; French et al., *J. Virol.*, 1989, 63, 3270; Pushpa-Rekha et al., *J. Biol. Chem.*, 1995, 270, 26993; Monaco et al., *J. Biol. Chem.*, 1994, 269, 347; DeVirgilio et al., *Yeast*, 1992, 8, 1043; Kanagasundaram et al., *Biochim. Biophys. Acta*, 1992, 1171, 198; Olsen et al., *Mol. Endocrinol.*, 1991, 5, 1246; Saul et al., *Appl.*

-16-

*Environ. Microbiol.*, 1990, 56, 3117; Yaoita et al., *Proc. Natl. Acad. Sci. USA*, 1990, 87, 7090; Rogers et al., *EMBO J.*, 1990, 9, 2273). In the context of the invention, "start codon" and "translation initiation codon" refer to 5 the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding a B7 protein, regardless of the sequence(s) of such codons. It is also known in the art that a 10 translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation region" refer to a portion of such an mRNA or gene that encompasses from about 25 to 15 about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous 20 nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term 25 includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over 30 native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of nucleases.

Specific examples of some preferred modified 35 oligonucleotides envisioned for this invention include

those containing phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are

5 oligonucleotides with phosphorothioates and those with  $\text{CH}_2\text{-NH-O-CH}_2$ ,  $\text{CH}_2\text{-N(CH}_3\text{)-O-CH}_2$  [known as a methylene (methylimino) or MMI backbone],  $\text{CH}_2\text{-O-N(CH}_3\text{)-CH}_2$ ,  $\text{CH}_2\text{-N(CH}_3\text{)-N(CH}_3\text{)-CH}_2$ , and  $\text{O-N(CH}_3\text{)-CH}_2\text{-CH}_2$  backbones, wherein the native phosphodiester backbone is represented as  $\text{O-P-O-CH}_2$ ). Also preferred are

10 oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Patent 5,034,506). Further preferred are oligonucleotides with  $\text{NR-C}(\text{*})\text{-CH}_2\text{-CH}_2$ ,  $\text{CH}_2\text{-NR-C}(\text{*})\text{-CH}_2$ ,  $\text{CH}_2\text{-CH}_2\text{-NR-C}(\text{*})$ ,  $\text{C}(\text{*})\text{-NR-CH}_2\text{-CH}_2$  and  $\text{CH}_2\text{-C}(\text{*})\text{-NR-CH}_2$  backbones, wherein "\*" represents O or S (known as amide

15 backbones; DeMesmaeker et al., WO 92/20823, published November 26, 1992). In other preferred embodiments, such as the peptide nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleobases being bound

20 directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al., *Science*, 1991, 254, 1497; U.S. Patent No. 5,539,082). Other preferred modified oligonucleotides may contain one or more substituted sugar moieties comprising one of the following at the 2'

25 position: OH, SH,  $\text{SCH}_3$ , F, OCN,  $\text{OCH}_3\text{OCH}_3$ ,  $\text{OCH}_3\text{O}(\text{CH}_2)_n\text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{NH}_2$ , or  $\text{O}(\text{CH}_2)_n\text{CH}_3$ , where n is from 1 to about 10;  $\text{C}_1$  to  $\text{C}_{10}$  lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN;  $\text{CF}_3$ ;  $\text{OCF}_3$ ; O-, S-, or N-alkyl; O-, S-, or N-alkenyl;  $\text{SOCH}_3$ ;  $\text{SO}_2\text{CH}_3$ ;  $\text{ONO}_2$ ;  $\text{NO}_2$ ;  $\text{N}_3$ ;

30 ~~NH<sub>2</sub>; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar~~

35

properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further 5 preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylamino-ethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 10 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>, also described in examples hereinbelow. (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486). Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-propoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions 15 on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of the 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group. 20 The oligonucleotides of the invention may additionally or alternatively include nucleobase modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include 25 nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-methylcytosine, 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentiobiosyl HMC, as well synthetic nucleobases, e.g., 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 30 7-deazaguanine, N<sup>6</sup>(6-aminohexyl)adenine and 2,6-diaminopurine (Kornberg, A., *DNA Replication*, 1974, W.H. Freeman & Co., San Francisco, 1974, pp. 75-77; Gebeyehu, G., et al., *Nucleic Acids Res.*, 1987, 15, 4513). Another preferred additional or alternative 35 modification of the oligonucleotides of the invention

-19-

involves chemically linking to the oligonucleotide one or more lipophilic moieties which enhance the cellular uptake of the oligonucleotide. Such lipophilic moieties may be linked to an oligonucleotide at several different positions 5 on the oligonucleotide. Some preferred positions include the 3' position of the sugar of the 3' terminal nucleotide, the 5' position of the sugar of the 5' terminal nucleotide, and the 2' position of the sugar of any nucleotide. The N<sup>6</sup> position of a purine nucleobase may also be utilized to 10 link a lipophilic moiety to an oligonucleotide of the invention (Gebeyehu, G., et al., *Nucleic Acids Res.*, 1987, 15, 4513). Such lipophilic moieties include but are not limited to a cholesteryl moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553), cholic acid 15 (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533), an 20 aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 111; Kabanov et al., *FEBS Lett.*, 1990, 259, 327; Svinarchuk et al., *Biochimie*, 1993, 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O- 25 hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969), or adamantane acetic acid (Manoharan et al., 30 *Tetrahedron Lett.*, 1995, 36, 3651), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923). Oligonucleotides comprising lipophilic moieties, and

methods for preparing such oligonucleotides, as disclosed in U.S. Patents No. 5,138,045, No. 5,218,105 and No. 5,459,255, the contents of which are hereby incorporated by reference.

5 The present invention also includes oligonucleotides which are chimeric oligonucleotides. "Chimeric" oligonucleotides or "chimeras," in the context of this invention, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one  
10 nucleotide. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An  
15 additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in  
20 cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense inhibition of gene expression. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. By way of  
25 example, such "chimeras" may be "gapmers," i.e., oligonucleotides in which a central portion (the "gap") of the oligonucleotide serves as a substrate for, e.g., RNase H, and the 5' and 3' portions (the "wings") are modified in such a fashion so as to have greater affinity for the  
30 target RNA molecule but are unable to support nuclease activity (e.g., 2'-fluoro- or 2'-methoxyethoxy substituted). Other chimeras include "wingmers," that is, oligonucleotides in which the 5' portion of the oligonucleotide serves as a substrate for, e.g., RNase H,  
35 whereas the 3' portion is modified in such a fashion so as

-21-

to have greater affinity for the target RNA molecule but is unable to support nuclease activity (e.g., 2'-fluoro- or 2'-methoxyethoxy substituted), or vice-versa.

The oligonucleotides in accordance with this invention 5 preferably comprise from about 8 to about 30 nucleotides. It is more preferred that such oligonucleotides comprise from about 15 to 25 nucleotides. As is known in the art, a nucleotide is a base-sugar combination suitably bound to an adjacent nucleotide through a phosphodiester, 10 phosphorothioate or other covalent linkage.

The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis.

Equipment for such synthesis is sold by several vendors 15 including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and 20 alkylated derivatives.

The oligonucleotides of the present invention can be utilized as therapeutic compounds, diagnostic tools and as research reagents and kits. The term "therapeutic uses" is intended to encompass prophylactic, palliative and curative 25 uses wherein the oligonucleotides of the invention are contacted with animal cells either *in vivo* or *ex vivo*. When contacted with animal cells *ex vivo*, a therapeutic use includes incorporating such cells into an animal after ~~treatment with one or more oligonucleotides of the~~

30 invention. While not intending to be bound to a particular utility, the *ex vivo* modulation of, e.g., T cell proliferation by the oligonucleotides of the invention can be employed in, for example, potential therapeutic modalities wherein it is desired to modulate the expression 35 of a B7 protein in APCs. As an example, oligonucleotides

that inhibit the expression of B7-1 proteins are expected to enhance the availability of B7-2 proteins on the surface of APCs, thus increasing the costimulatory effect of B7-2 on T cells *ex vivo* (Levine et al., *Science*, 1996, 272, 5 1939).

For therapeutic uses, an animal suspected of having a disease or disorder which can be treated or prevented by modulating the expression or activity of a B7 protein is, for example, treated by administering oligonucleotides in 10 accordance with this invention. The oligonucleotides of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an oligonucleotide to a suitable pharmaceutically acceptable diluent or carrier. Workers in the field have identified 15 antisense, triplex and other oligonucleotide compositions which are capable of modulating expression of genes implicated in viral, fungal and metabolic diseases. Antisense oligonucleotides have been safely administered to humans and several clinical trials are presently underway. 20 It is thus established that oligonucleotides can be useful therapeutic instrumentalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

The oligonucleotides of the present invention can be 25 further used to detect the presence of B7-specific nucleic acids in a cell or tissue sample. For example, radiolabeled oligonucleotides can be prepared by  $^{32}\text{P}$  labeling at the 5' end with polynucleotide kinase (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, Cold Spring 30 Harbor Laboratory Press, 1989, Volume 2, pg. 10.59).

Radiolabeled oligonucleotides are then contacted with cell or tissue samples suspected of containing B7 message RNAs (and thus B7 proteins), and the samples are washed to remove unbound oligonucleotide. Radioactivity remaining in 35 the sample indicates the presence of bound oligonucleotide,

which in turn indicates the presence of nucleic acids complementary to the oligonucleotide, and can be quantitated using a scintillation counter or other routine means. Expression of nucleic acids encoding these proteins 5 is thus detected.

Radiolabeled oligonucleotides of the present invention can also be used to perform autoradiography of tissues to determine the localization, distribution and quantitation of B7 proteins for research, diagnostic or therapeutic 10 purposes. In such studies, tissue sections are treated with radiolabeled oligonucleotide and washed as described above, then exposed to photographic emulsion according to routine autoradiography procedures. The emulsion, when developed, yields an image of silver grains over the 15 regions expressing a B7 gene. Quantitation of the silver grains permits detection of the expression of mRNA molecules encoding these proteins and permits targeting of oligonucleotides to these areas.

Analogous assays for fluorescent detection of 20 expression of B7 nucleic acids can be developed using oligonucleotides of the present invention which are conjugated with fluorescein or other fluorescent tags instead of radiolabeling. Such conjugations are routinely accomplished during solid phase synthesis using 25 fluorescently-labeled amidites or controlled pore glass (CPG) columns. Fluorescein-labeled amidites and CPG are available from, e.g., Glen Research, Sterling VA.

The present invention employs oligonucleotides targeted to nucleic acids encoding B7 proteins and 30 oligonucleotides targeted to nucleic acids encoding such proteins. Kits for detecting the presence or absence of expression of a B7 protein may also be prepared. Such kits include an oligonucleotide targeted to an appropriate gene, i.e., a gene encoding a B7 protein. Appropriate kit and 35 assay formats, such as, e.g., "sandwich" assays, are known

-24-

in the art and can easily be adapted for use with the oligonucleotides of the invention. Hybridization of the oligonucleotides of the invention with a nucleic acid encoding a B7 protein can be detected by means known in the 5 art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection systems. Kits for detecting the presence or absence of a B7 protein may also be prepared.

10 In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleotides. For example, adenine and thymine are complementary nucleobases which pair through 15 the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or 20 RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by 25 nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the 30 DNA or RNA target. It is understood in the art that an oligonucleotide need not be 100% complementary to its target DNA sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the oligonucleotide to the target DNA or RNA molecule 35 interferes with the normal function of the target DNA or

-25-

RNA to cause a decrease or loss of function, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding is desired,

5 i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment, or in the case of *in vitro* assays, under conditions in which the assays are performed.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the

10 skill of those in the art. In general, for therapeutics, a patient in need of such therapy is administered an oligonucleotide in accordance with the invention, commonly in a pharmaceutically acceptable carrier, in doses ranging from 0.01  $\mu$ g to 100 g per kg of body weight depending on

15 the age of the patient and the severity of the disorder or disease state being treated. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease or disorder, its severity and the overall condition of the

20 patient, and may extend from once daily to once every 20 years. Following treatment, the patient is monitored for changes in his/her condition and for alleviation of the symptoms of the disorder or disease state. The dosage of the oligonucleotide may either be increased in the event

25 the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disorder or disease state is observed, or if the disorder or disease state has been ablated.

30 ~~In some cases, it may be more effective to treat a patient with an oligonucleotide of the invention in conjunction with other therapeutic modalities in order to increase the efficacy of a treatment regimen. In the context of the invention, the term "treatment regimen" is~~

35 meant to encompass therapeutic, palliative and prophylactic

modalities. In a preferred embodiment, the oligonucleotides of the invention are used in conjunction with an anti-inflammatory and/or immunosuppressive agent, preferably one or more antisense oligonucleotides targeted 5 to an intercellular adhesion molecule (ICAM), preferably to ICAM-1. Other anti-inflammatory and/or immunosuppressive agents that may be used in combination with the oligonucleotides of the invention include, but are not limited to, soluble ICAM proteins (e.g., sICAM-1), 10 antibody-toxin conjugates, prednisone, methylprednisolone, azathioprine, cyclophosphamide, cyclosporine, interferons, sympathomimetics, conventional antihistamines (histamine H<sub>1</sub> receptor antagonists, including, for example, brompheniramine maleate, chlorpheniramine maleate, 15 dexchlorpheniramine maleate, tripolidine HCl, carbinoxamine maleate, clemastine fumarate, dimenhydrinate, diphenhydramine HCl, diphenylpyraline HCl, doxylamine succinate, tripeleannamine citrate, tripeleannamine HCl, cyclizine HCl, hydroxyzine HCl, meclizine HCl, methdilazine 20 HCl, promethazine HCl, trimeprazine tartrate, azatadine maleate, cyproheptadine HCl, terfenadine, etc.), histamine H<sub>2</sub> receptor antagonists (e.g., ranitidine). See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 302-336 and 2516-2522). When used with the compounds of the invention, such 25 agents may be used individually, sequentially, or in combination with one or more other such agents.

In another preferred embodiment of the invention, an antisense oligonucleotide targeted to one B7 mRNA species 30 (e.g., B7-1) is used in combination with an antisense oligonucleotide targeted to a second B7 mRNA species (e.g., B7-2) in order to inhibit the costimulatory effect of B7 molecules to a more extensive degree than can be achieved with either oligonucleotide used individually. In a 35 related version of this embodiment, two or more

-27-

oligonucleotides of the invention, each targeted to an alternatively spliced B7-1 or B7-2 mRNA, are combined with each other in order to inhibit expression of both forms of the alternatively spliced mRNAs. It is known in the art 5 that, depending on the specificity of the modulating agent employed, inhibition of one form of an alternatively spliced mRNA may not result in a sufficient reduction of expression for a given condition to be manifest. Thus, such combinations may, in some instances, be desired to 10 inhibit the expression of a particular B7 gene to an extent necessary to practice one of the methods of the invention.

Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the 15 oligonucleotide is administered in maintenance doses, ranging from 0.01  $\mu$ g to 100 g per kg of body weight, once or more daily, to once every 20 years. In the case of an individual known or suspected of being prone to an autoimmune or inflammatory condition, prophylactic effects 20 may be achieved by administration of preventative doses, ranging from 0.01  $\mu$ g to 100 g per kg of body weight, once or more daily, to once every 20 years. In like fashion, an individual may be made less susceptible to an inflammatory condition that is expected to occur as a result of some 25 medical treatment, e.g., graft versus host disease resulting from the transplantation of cells, tissue or an organ into the individual.

The pharmaceutical compositions of the present invention may be administered in a number of ways depending 30 upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, 35 including by nebulizer; intratracheal, intranasal,

epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or 5 intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, 10 drops, suppositories, sprays, liquids and powders.

Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

15 Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

20 Compositions for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on severity and responsiveness of 25 the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the 30 body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC<sub>50</sub>'s found to be 35 effective in *in vitro* and *in vivo* animal models. In

-29-

general, dosage is from 0.01  $\mu$ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years.

The following examples illustrate the invention and 5 are not intended to limit the same. Those skilled in the art will recognize, or be able to ascertain through routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of the 10 present invention.

The following examples are provided for illustrative purposes only and are not intended to limit the invention.

#### EXAMPLES

##### Example 1: Synthesis of Nucleic Acids

###### 15 Oligonucleotides

Oligonucleotides were synthesized on an automated DNA synthesizer using standard phosphoramidite chemistry with oxidation using iodine.  $\beta$ -Cyanoethyldiisopropyl phosphoramidites were purchased from Applied Biosystems 20 (Foster City, CA). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of 3H-1,2-benzodithiole-3-one-1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation cycle wait step was increased to 68 25 seconds and was followed by the capping step.

The 2'-fluoro phosphorothioate oligonucleotides of the invention were synthesized using 5'-dimethoxytrityl-3'-phosphoramidites and prepared as disclosed in U.S. patent application Serial No. 463,358, filed January 11, 1990, and 30 Serial No. 566,977, filed August 13, 1990, which are assigned to the same assignee as the instant application and which are incorporated by reference herein. The 2'-fluoro oligonucleotides were prepared using phosphoramidite chemistry and a slight modification of the standard DNA

-30-

synthesis protocol: deprotection was effected using methanolic ammonia at room temperature.

The 2'-methoxy (2'-O-methyl) oligonucleotides of the invention were synthesized using 2'-methoxy  $\beta$ -5 cyanoethylisopropyl-phosphoramidites (Chemgenes, Needham MA) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base is increased to 360 seconds. Other 2'-alkoxy oligonucleotides are synthesized by a modification of this 10 method, using appropriate 2'-modified amidites such as those available from Glen Research, Inc., Sterling, VA. The 3'-base used to start the synthesis was a 2'-deoxyribonucleotide. The 2'-O-propyl oligonucleotides of the invention are prepared by a slight modification of this 15 procedure.

The 2' methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>) oligonucleotides of the invention were synthesized according to the method of Martin, *Helv. Chim. Acta* 1995, 78, 486. For ease of synthesis, the last nucleotide was a deoxynucleotide. All 20 2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> cytosines were 5-methyl cytosines, which were synthesized according to the following procedures.

**Synthesis of 5-Methyl cytosine monomers:**

2,2'-Anhydro[1-( $\beta$ -D-arabinofuranosyl)-5-methyluridine]  
5-Methyluridine (ribosylthymine, commercially 25 available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. 30 After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 35 400 mL). The solution was poured into fresh ether (2.5 L)

-31-

to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid which was crushed to a light tan powder (57 g, 85% crude yield). The material was used as is for further 5 reactions.

**2'-O-Methoxyethyl-5-methyluridine**

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel 10 and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 15 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3) containing 0.5% Et<sub>3</sub>NH. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and adsorbed onto silica (150 g) prior to loading 20 onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue 25 dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one 30 hour. ~~Methanol (170 mL) was then added to stop the reaction.~~ HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH<sub>3</sub>CN (200 mL). The residue was dissolved in CHCl<sub>3</sub> (1.5 L) and extracted with 2x500 mL of saturated NaHCO<sub>3</sub>, and 2x500 mL 35 of saturated NaCl. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>.

-32-

filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et<sub>3</sub>NH. The pure fractions were evaporated 5 to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

10 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was 15 monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl<sub>3</sub> (800 mL) and extracted with 2x200 mL of saturated sodium 20 bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl<sub>3</sub>. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and 25 eluted using EtOAc/Hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O- 30 acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH<sub>3</sub>CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH<sub>3</sub>CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl<sub>3</sub> 35 was added dropwise, over a 30 minute period, to the stirred

-33-

solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added to the later solution dropwise, over a 45 minute period. The resulting reaction mixture was stored 5 overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO<sub>3</sub>, and 2x300 mL of saturated NaCl, 10 dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5'-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH<sub>3</sub>OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred 20 to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH<sub>3</sub> gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with 25 saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N'-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5'-methylcytidine**

30 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5'-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was 35 evaporated and the residue azeotroped with MeOH (200 mL).

-34-

The residue was dissolved in CHCl<sub>3</sub> (700 mL) and extracted with saturated NaHCO<sub>3</sub> (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO<sub>4</sub> and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica 5 column using EtOAc/Hexane (1:1) containing 0.5% Et<sub>3</sub>NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

**N<sup>4</sup>-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

10 N<sup>4</sup>-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxytetra(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting 15 mixture was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO<sub>3</sub> (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH<sub>2</sub>Cl<sub>2</sub> (300 mL), and the extracts were 20 combined, dried over MgSO<sub>4</sub>, and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc\Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

25 2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminoxyethyl) nucleoside amidites

**2'- (Dimethylaminoxyethoxy) nucleoside amidites**

2'- (Dimethylaminoxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminoxyethyl) nucleoside 30 amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected

-35-

with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

**5'-O-tert-Butyldiphenylsilyl-02'-anhydro-5-methyluridine**

5       O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 mL) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane 10 (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned 15 between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the 20 solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

25       **5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene 30 glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided.

5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>--2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was

-36-

sealed and heated in an oil bath until an internal temperature of 160°C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and 5 Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme 10 conditions used to remove the ethylene glycol.

[Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica 15 gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less 20 pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-  
5-methyluridine**

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5- 25 methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxypthalimide (7.24g, 44.36mmol). It was then dried over P<sub>2</sub>O<sub>5</sub> under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF 30 (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. 35 After the addition was complete, the reaction was stirred

-37-

for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40),  
5 to get

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine

10 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH<sub>2</sub>Cl<sub>2</sub>, and  
15 the combined organic phase was washed with water, brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solution was concentrated to get 2'-O-(aminoxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting  
20 mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get  
5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%).

25 5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine  
5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium  
30 cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC

-38-

(5% MeOH in  $\text{CH}_2\text{Cl}_2$ ). Aqueous  $\text{NaHCO}_3$  solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous  $\text{Na}_2\text{SO}_4$ , evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in 5 MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C 10 for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5%  $\text{NaHCO}_3$  (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous 15  $\text{Na}_2\text{SO}_4$  and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in  $\text{CH}_2\text{Cl}_2$ , to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

20 2'-O-(dimethylaminoxyethyl)-5-methyluridine  
Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in  $\text{CH}_2\text{Cl}_2$ ). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$ , to get  
25 30 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine  
2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over  $\text{P}_2\text{O}_5$  under high vacuum overnight at 35 40°C. It was then co-evaporated with anhydrous pyridine

- 39 -

(20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture 5 was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine 10 (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine 15 (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetraazonide (0.29g, 1.67mmol) was added and dried over P205 under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 20 2-cyanoethyl-N,N,N1,N1-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was 25 evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous  $\text{NaHCO}_3$  (40mL). Ethyl acetate layer was dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get

30 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

2'-(Aminooxyethoxy) nucleoside amidites  
2'-(Aminooxyethoxy) nucleoside amidites [also known in the 35 art as 2'-O-(aminoxyethyl) nucleoside amidites] are

- 40 -

prepared as described in the following paragraphs.

Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

5                   N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-  
                  ethylacetyl)- 5'-O-(4,4'-dimethoxytrityl)guanosine-  
                  3'-[(2-cyanoethyl)- N,N-diisopropylphosphoramidite]  
                  The 2'-O-aminoxyethyl guanosine analog may be  
                  obtained by selective 2'-O-alkylation of diaminopurine  
                  riboside. Multigram quantities of diaminopurine riboside  
10                  may be purchased from Schering AG (Berlin) to provide 2'-O-  
                  (2-ethylacetyl) diaminopurine riboside along with a minor  
                  amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl)  
                  diaminopurine riboside may be resolved and converted to 2'-  
                  O-(2-ethylacetyl)guanosine by treatment with adenosine  
15                  deaminase. (McGee, D. P. C., Cook, P. D., Guinossso, C. J.,  
                  WO 94/02501 A1 940203.) Standard protection procedures  
                  should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-  
                  dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-  
                  diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-  
20                  dimethoxytrityl)guancsine which may be reduced to provide  
                  2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-  
                  5'-O-(4,4'-dimethoxytrityl)guanosine. As before the  
                  hydroxyl group may be displaced by N-hydroxypthalimide via  
                  a Mitsunobu reaction, and the protected nucleoside may  
25                  phosphitylated as usual to yield 2-N-isobutyryl-6-O-  
                  diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-  
                  dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-  
                  diisopropylphosphoramidite].

30                  2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside  
                  amidites

                  2'-dimethylaminoethoxyethoxy nucleoside amidites (also  
                  known in the art as 2'-O-dimethylaminoethoxyethyl, i.e.,  
                  2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>, or 2'-DMAEOE nucleoside amidites) are

-41-

prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

5 2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O<sub>2</sub>-, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium 10 bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155 C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess 15 phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene 20 chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethyl aminoethoxy)ethyl]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour.

30 The reaction mixture is poured into water (200 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2x200 mL). The combined CH<sub>2</sub>Cl<sub>2</sub> layers are washed with saturated NaHCO<sub>3</sub> solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel

-42-

chromatography using MeOH:CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>3</sub>N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-

5 (cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

15 **Purification:**

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides were purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Analytical gel electrophoresis was accomplished in 20% acrylamide, 8 M urea, 45 mM Tris-borate buffer, pH 7.0. Oligodeoxynucleotides and their phosphorothioate analogs were judged from electrophoresis to be greater than 80% full length material.

**B7 Antisense Oligonucleotides**

A series of oligonucleotides with sequences designed to hybridize to the published human B7-1 (hB7-1) and murine (mB7-1) mRNA sequences (Freeman et al., *J. Immunol.*, 1989, 143, 2714, and Freeman et al., *J. Exp. Med.*, 1991, 174, 625 respectively). The sequences of and modifications to these oligonucleotides, and the location of each of their target sites on the hB7-1 mRNA, are given in Tables 1 and 2. Similarly, a series of oligonucleotides with sequences

-43-

designed to hybridize to the human B7-2 (hB7-2) and murine B7-2 (mB7-2) mRNA published sequences (respectively, Azuma et al., *Nature*, 1993, 366, 76; Chen et al., *J. Immunol.*, 1994, 152, 4929) were synthesized. The sequences of and 5 modifications to these oligonucleotides and the location of each of their target sites on the hB7-2 mRNA are described in Tables 3 and 4. Antisense oligonucleotides targeted to ICAM-1, including ISIS 2302 (SEQ ID NO: 17), have been described in U.S. Patent No. 5,514,788, which issued May 7, 10 1996, hereby incorporated by reference. ISIS 1082 (SEQ ID NO: 102) and ISIS 3082 (SEQ ID NO: 101) have been previously described (Stepkowski et al., *J. Immunol.*, 1994, 153, 5336).

Subsequent to their initial cloning, alternative 15 splicing events of B7 transcripts have been reported. The reported alternative splicing for B7-1 is relatively simple, in that it results in messages extended 5' relative to the 5' terminus of the human and murine B7-1 cDNA sequences originally reported (Borriello et al., *J. Immunol.*, 1994, 153, 5038; Inobe et al., *J. Immunol.*, 1996, 157, 588). In order to retain the numbering of the B7-1 sequences found in the references initially reporting B7-1 sequences, positions within these 5' extensions of the initially reported sequences have been given negative 20 numbers (beginning with position -1, the most 3' base of the 5' extension) in Tables 1 and 2. The processing of murine B7-2 transcripts is considerably more complex than that so far reported for B7-1; for example, at least five 25 distinct murine B7-2 mRNAs, and at least two distinct human B7-2 mRNAs, can be produced by alternative splicing events (Borriello et al., *J. Immunol.*, 1995, 155, 5490; Freeman et al., WO 95/03408, published February 2, 1995; see also Jellis et al., *Immunogenet.*, 1995, 42, 85). The nature of 30 these splicing events is such that different 5' exons are used to produce distinct B7-2 mRNAs, each of which has a 35

- 44 -

unique 5' sequence but which share a 3' portion consisting of some or all of the B7-2 sequence initially reported. As a result, positions within the 5' extensions of B7-2 messages cannot be uniquely related to a position within 5 the sequence initially reported. Accordingly, in Table 3, a different set of coordinates (corresponding to those of SEQ ID NO: 1 of WO 95/03408) and, in Table 4, the exon number (as given in Borriello et al., *J. Immunol.*, 1995, 155, 5490) is used to specify the location of targeted 10 sequences which are not included in the initially reported B7-2 sequence. Furthermore, although these 5' extended messages contain potential in-frame start codons upstream from the ones indicated in the initially published sequences, for simplicity's sake, such additional potential 15 start codons are not indicated in the description of target sites in Tables 1-4.

In Tables 1-4, the following abbreviations are used: UTR, untranslated region; ORF, open reading frame; tIR, translation initiation region; tTR, translation termination 20 region; FITC, fluorescein isothiocyanate. Chemical modifications are indicated as follows. Residues having 2' fluoro (2'F), 2'-methoxy (2'MO) or 2'-methoxyethoxy (2'ME) modification are emboldened, with the type of modification being indicated by the respective abbreviations. Unless 25 otherwise indicated, interresidue linkages are phosphodiester linkages; phosphorothioate linkages are indicated by an "S" in the superscript position (e.g., T<sup>S</sup>A). Target positions are numbered according to Freeman et al., *J. Immunol.*, 1989, 143:2714 (human B7-1 cDNA sequence; 30 Table 1), Freeman et al., *J. Exp. Med.*, 1991, 174, 625 (murine B7-1 cDNA sequence; Table 2), Azuma et al., *Nature*, 1993, 366:76 (human B7-2 cDNA sequence; Table 3) and Chen et al., *J. Immunol.*, 1994, 152:4929 (murine B7-2 cDNA sequence; Table 4). Nucleotide base codes are as given in 35 37 C.F.R. § 1.822(b)(1).

TABLE 1  
Sequences of Oligonucleotides Targeted to Human B7-1 mRNA

5	ISIS #	Target Position; Site (and/or Description)	Oligonucleotide Sequence (5' -> 3') and Chemical Modifications	SEQ ID NO:
13797	0053-0072; 5' UTR		G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> P <sup>s</sup> G <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A	22
13798	0132-0151; 5' UTR		G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A	23
13799	0138-0157; 5' UTR		G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T	24
13800	0158-0177; 5' UTR		A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T	25
10	13801	0193-0212; 5' UTR	G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C	26
	13802	0217-0236; 5' UTR	G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C	27
	13803	0226-0245; 5' UTR	T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A	28
	13804	0246-0265; 5' UTR	A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G	29
	13805	0320-0339; TIR	C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C	30
15	13806	0380-0399; 5' ORF	G <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C	31
	13807	0450-0469; 5' ORF	C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C	32
	13808	0568-0587; 5' ORF	C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C	33
	13809	0634-0653; central ORF	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A	51
	13810	0829-0848; central ORF	C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C	34
20	13811	1102-1121; 3' ORF	G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C	35

13812	1254-1273; 3' -UTR	G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C	36
13872	(scrambled # 13812)	A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T	52
12361	0056-0075; 5' UTR	T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C	38
12348	0056-0075; 5' UTR	T C A G G G T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A C T T C (2' ME)	38
5	12473 0056-0075; 5' UTR	T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A C T T C (2' F1)	38
12362	0143-0162; 5' UTR	A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A	39
12349	0143-0162; 5' UTR	A G G G T G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A (2' ME)	39
12474	0143-0162; 5' UTR	A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A (2' F1)	39
12363	0315-0334; tIR	C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> S <sup>s</sup> T <sup>s</sup> S <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> S <sup>s</sup> G <sup>s</sup> C	40
10	12350 0315-0334; tIR	C T C C G T G T G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C A T G G C (2' ME)	40
12475	0315-0334; tIR	C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> S <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C (2' F1)	40
12364	0334-0353; 5' ORF	G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> S <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C	41
12351	0334-0353; 5' ORF	G G A T G G G T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> S <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C (2' ME)	41
12476	0334-0353; 5' ORF	G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> S <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C (2' F1)	41
15	12365 0387-0406; 5' ORF	T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C	42
12352	0387-0406; 5' ORF	T G A G A A S <sup>s</sup> S <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> S <sup>s</sup> C A G C A C (2' ME)	42
12477	0387-0406; 5' ORF	T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> S <sup>s</sup> C (2' F1)	42
12366	0621-0640; central ORF	G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> S <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C	43
12353	0621-0640; central ORF	G G G C G C <sup>s</sup> S <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T C A C (2' ME)	43

- 47 -

TABLE 2  
Sequences of Oligonucleotides Targeted to Murine B7-1 mRNA

ISIS #	Target Position; Site	Oligonucleotide Sequence (5'-->3') and Chemical Modifications	SEQ NO:	SEQ ID
14419	0009-0028; 5' UTR	A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A	53	
14420	0041-0060; 5' UTR	G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A	54	
14421	0071-0091; 5' UTR	G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G	55	
10	14422 0109-0128; 5' UTR	G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C	56	
14423	0114-0133; 5' UTR	T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup>	57	
14424	0168-0187; 5' UTR	A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> S <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A	58	
14425	0181-0200; 5' UTR	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C	59	
14426	0208-0217; 5' UTR	C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A	60	
14427	0242-0261; tIR	A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> T <sup>s</sup> S <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A	61	
14428	0393-0412; 5' ORF	C <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T	62	
14909	0478-0497; 5' ORF	C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup>	63	
14910	0569-0588; central ORF	G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C	64	
14911	0745-0764; central ORF	T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup>	65	
20	14912 0750-0769; central ORF	G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A	66	
14913	0825-0844; 3' ORF	T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A	67	

- 49 -

14914	0932-0951; 3' ORF	C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> C	68
14915	1001-1020; 3' ORF	C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A	69
14916	1125-1144; tTR	C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G	70
14917	1229-1248; 3' UTR	T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A	71
5	14918 1329-1348; 3' UTR	G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T	72
14919	1377-1393; 3' UTR	C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C	73
12912	-0067 to -0049; 5' UTR (2' MO)	G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A	74
12913	-0067 to -0047; 5' UTR (2' MO)	G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A	75
13496	-0067 to -0047; 5' UTR (2' ME)	G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A	75
10	13497 -0067 to -0047; 5' UTR (2' ME)	G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A	75

TABLE 3  
Sequences of Oligonucleotides Targeted to Human B7-2 mRNA

15

ISIS #	Target Position*, Site**	Oligonucleotide Sequence (5' ->3')	SEQ ID NO:
9133	1367-1386; 3' -UTR	T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> A	3

10715	scrambled control of # 9133	G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A	76
9134	1333-1352; 3'-UTR	C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G	4
9135	1211-1230; 3'-UTR	T <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup>	5
9136	1101-1120; tTR	A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> S <sup>s</sup> T <sup>s</sup>	6
5	10716 (scrambled # 9136)	A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup>	77
9137	0054-0074; 5'-UTR	G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup>	7
9138	0001-0020; 5'-UTR	C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup>	8
9139	0133-0152; tIR	C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> S <sup>s</sup> A <sup>s</sup> T <sup>s</sup>	9
10877	(scrambled # 9139)	A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	78
10367	0073-0092; 5'-UTR	G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G	10
10368	0240-0259; 5' ORF	T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> S <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G	11
10369	1122-1141; 3'-UTR	T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> S <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> S <sup>s</sup> T <sup>s</sup> T <sup>s</sup>	12
10370	1171-1190; 3'-UTR	A <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> S <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> S <sup>s</sup> G	13
10371	1233-1252; 3'-UTR	G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup>	14
15	10372 1353-1372; 3'-UTR	C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> S <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C	15
11149	0019-0034; 5'-UTR	T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C	79
11151	0020-0034; 5'-UTR	T <sup>s</sup> P <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C	80
11150	0021-0034; 5'-UTR	T <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C	81
10373	0011-0030; 5'-UTR	T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C	16

10721	(scrambled # 10373)	C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C	82
10729	(5' FITC # 10373)	T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C	16
10782	(5' cholesterol # 10373)	T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C	16
	# 10373 Deletion Derivatives:		
5	10373 0011-0030; 5' -UTR	T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C	16
10888	0011-0026; 5' -UTR	A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C	83
10889	0015-0030; 5' -UTR	T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	84
10991	0015-0024; 5' -UTR	C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	85
10992	0015-0025; 5' -UTR	G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	86
10	10993 0015-0026; 5' -UTR	A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	87
10994	0015-0027; 5' -UTR	G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	88
10995	0015-0028; 5' -UTR	C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	89
10996	0015-0029; 5' -UTR	G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	90
	11232 0017-0029; 5' UTR	G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T	91
15	# 10996 Derivatives:		
10996	0015-0029; 5' -UTR	G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	90
11806	(scrambled # 10996)	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T	92
11539	(fully 2' MO # 10996)	G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	(2' MO)
11540	(control for # 11539)	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T	(2' MO)
			92

	11541	(# 10996 7-base "gapmer")	G <sup>s</sup> C <sup>s</sup> G <sup>A</sup> <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	(2' MO)	90
	11542	(control for # 11541)	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T	(2' MO)	92
	11543	(# 10996 9-base "gapmer")	G <sup>s</sup> C <sup>s</sup> G <sup>A</sup> <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	(2' MO)	90
	11544	(control for # 11543)	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T	(2' MO)	92
5	11545	(# 10996 5' "wingmer")	G <sup>s</sup> C <sup>s</sup> G <sup>A</sup> <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	(2' MO)	90
	11546	(control for # 11545)	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T	(2' MO)	92
	11547	(# 10996 3' "wingmer")	G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	(2' MO)	90
	11548	(control for # 11547)	G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T	(2' MO)	92
	12496	((2' -5') A <sub>4</sub> # 10996)	G C G A G C T C C C C G T A C		90
	13107	((2' -5') A <sub>4</sub> # 10996)	G <sup>s</sup> C <sup>s</sup> G <sup>A</sup> <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C		90
10	12492	((2' -5') A <sub>4</sub> # 10996)	G <sup>s</sup> C <sup>s</sup> G <sup>A</sup> <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	(2' MO)	90
	12495	((2' -5') A <sub>4</sub> # 10996)	G <sup>s</sup> C <sup>s</sup> G <sup>A</sup> <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C	(2' MO)	90
	12887	(1-24 of SEQ ID NO: 1 of WO 95/03408; alternative mRNA)	G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> sC <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> - T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup>	(2' MO)	93
	12888	(1-22 of SEQ ID NO: 1 of WO 95/03408; alternative mRNA)	G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> sC <sup>s</sup> T <sup>s</sup> G <sup>s</sup>	(2' MO)	94
15	12889	(1-19 of SEQ ID NO: 1 of WO 95/03408; alternative mRNA)	G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup>	(2' MO)	95

- 53 -

12890	0001-0024	C <sup>S</sup> T <sup>S</sup> C <sup>S</sup> C <sup>S</sup> G <sup>S</sup> T <sup>S</sup> A <sup>S</sup> C <sup>S</sup> T <sup>S</sup> C <sup>S</sup> T <sup>S</sup> A <sup>S</sup> G <sup>S</sup> C <sup>S</sup> - s <sub>T<sup>S</sup>C<sup>S</sup>T<sup>S</sup>T</sub>	96 (2', MO)
12891	0001-0022	C <sup>S</sup> C <sup>S</sup> C <sup>S</sup> G <sup>S</sup> T <sup>S</sup> A <sup>S</sup> C <sup>S</sup> T <sup>S</sup> C <sup>S</sup> T <sup>S</sup> A <sup>S</sup> G <sup>S</sup> C <sup>S</sup> T <sup>S</sup> C <sup>S</sup> T (MO)	97 (2', MO)
12892	0001-0020	C <sup>S</sup> C <sup>S</sup> G <sup>S</sup> T <sup>S</sup> A <sup>S</sup> C <sup>S</sup> T <sup>S</sup> C <sup>S</sup> T <sup>S</sup> A <sup>S</sup> G <sup>S</sup> C <sup>S</sup> T <sup>S</sup> C <sup>S</sup> C (2', MO)	98 (2', MO)

TABLE 4  
Sequences of Oligonucleotides Targeted to Murine B7-2 mRNA

ISIS #	Target Position; Site	Oligonucleotide Sequence (5'->3')	SEQ ID NO:
11347	1094-1113; 3' UTR	A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A	121
11348	1062-1081; 3' UTR	T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A	122
11349	1012-1031; 3' UTR	T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T	123
11350	0019-1138; 5' UTR	G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G	124
11351	0037-0056; 5' UTR	A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G	103
11352	0089-0108; TIR	C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G	104
11353	0073-0092; TIR	C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C	105
11354	0007-0026; 5' UTR	C <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C	106
11695	0058-0077; 5' UTR	G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> S <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G	107

10	ISIS #	Target Position; Site	Oligonucleotide Sequence (5' ->3')	SEQ ID NO:
	11696	0096-0117; tIR	G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G	108
	11866	(scrambled # 11696)	C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A	109
5	11697	0148-0167; 5' ORF	T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> S <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C	110
	11698	0319-0338; 5' ORF	G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> S <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C	111
	11699	0832-0851; 3' ORF	A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> A <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T	112
	11700	0753-0772; 3' ORF	T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> A <sup>s</sup> A <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C	113
	11701	0938-0957; 3' ORF	G <sup>s</sup> A <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T	114
	11702	0890-0909; 3' ORF	G <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T	115
	11865	(scrambled # 11702)	C <sup>s</sup> T <sup>s</sup> A <sup>s</sup> G <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> G	116
10	11703	1003-1022; tTR	T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> A <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> C	117
	13100	Exon 1 (Borriello et al., J. Immun., 1995, 155, 5490; 5' UTR of alternative mRNA)	G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup> S <sup>s</sup> A <sup>s</sup> S <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A	118
	13101	Exon 4 (Borriello et al.; 5' UTR of alternative mRNA)	C <sup>s</sup> T <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> A <sup>s</sup> S <sup>s</sup> T <sup>s</sup> A <sup>s</sup> S <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> S <sup>s</sup> T <sup>s</sup> T <sup>s</sup> C <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup>	119
	13102	Exon 5 (Borriello et al.; 5' UTR of alternative mRNA)	G <sup>s</sup> C <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup> G <sup>s</sup> T <sup>s</sup> A <sup>s</sup> A <sup>s</sup> G <sup>s</sup> C <sup>s</sup> C <sup>s</sup> T <sup>s</sup> G <sup>s</sup> A <sup>s</sup> G <sup>s</sup> T <sup>s</sup>	120

**cDNA clones:**

A cDNA encoding the sequence for human B7-1 was isolated by using the reverse transcription/polymerase chain reaction (RT-PCR). Poly A+ RNA from Daudi cells (ATCC accession No. CCL 213) was reverse transcribed using 5 oligo-dT primer under standard conditions. Following a 30 minute reaction at 42°C and heat inactivation, the reaction mixture (20 µL) was brought to 100 µL with water. A 10 µL aliquot from the RT reaction was then amplified in a 50 µL 10 PCR reaction using the 5' primer,

5'-GAT-CAG-GGT-ACC-CCA-AAG-AAA-AAG-TGA-TTT-GTC-ATT-GC-  
3'

(sense, SEQ ID NO: 20), and the 3' primer,  
5'-GAT-AGC-CTC-GAG-GAT-AAT-GAA-TTG-GCT-GAC-AAG-AC-3'  
15 (antisense, SEQ ID NO: 21).

The primers included unique restriction sites for subcloning of the PCR product into the vector pcDNA-3 (Invitrogen, San Diego, CA). The 5' primer was designed to have identity with bases 1 to 26 of the published human B7-1 sequence (Freeman et al., *J. Immunol.*, 1989, 143, 2714; positions 13-38 of the primer) and includes a Kpn I restriction site (positions 7-12 of the primer) for use in cloning. The 3' primer was designed to be complementary to bases 1450 to 1471 of the published sequence for B7-1 20 (positions 14-35 of the primer) and includes a Xho I restriction site (positions 7-12 of the primer). Following PCR, the reaction was extracted with phenol and precipitated using ethanol. The product was digested with 25 the appropriate restriction enzymes and the full-length fragment purified by agarose gel and ligated into the vector pcDNA-3 (Invitrogen, San Diego, CA) prepared by digesting with the same enzymes. The resultant construct, pcB7-1, was confirmed by restriction mapping and DNA sequence analysis using standard procedures. A mouse B7-1 30

-56-

clone, pcmb7-1, was isolated in a similar manner by RT-PCR of RNA isolated from a murine B-lymphocyte cell line, 70Z3.

A cDNA encoding the sequence for human B7-2, position 1 to 1391, was also isolated by RT-PCR. Poly A+ RNA from 5 Daudi cells (ATCC accession No. CCL 213) was reverse transcribed using oligo-dT primer under standard conditions. Following a 30 minute reaction at 42°C and heat inactivation, the reaction mixture (20  $\mu$ L) was brought to 100  $\mu$ L with water. A 10  $\mu$ L aliquot from the RT reaction 10 was then amplified in a 50  $\mu$ L PCR reaction using the 5' primer,

5'-GAT-CAG-GGT-ACC-AGG-AGC-CTT-AGG-AGG-TAC-GG-3'  
(sense, SEQ ID NO: 1), and the 3' primer,

5'-GAT-AGC-CTC-GAG-TTA-TTT-CCA-GGT-CAT-GAG-CCA-3'  
15 (antisense, SEQ ID NO: 2).

The 5' primer was designed to have identity with bases 1-20 of the published B7-2 sequence (Azuma et al., *Nature*, 1993, 366, 76 and Genbank Accession No. L25259; positions 13-32 of the primer) and includes a Kpn I site (positions 20 7-12 of the primer) for use in cloning. The 3' primer was designed to have complementarity to bases 1370-1391 of the published sequence for B7-2 (positions 13-33 of the primer) and includes an Xho I restriction site (positions 7-12 of the primer). Following PCR, the reaction was extracted 25 with phenol and precipitated using ethanol. The product was digested with Xho I and Kpn I, and the full-length fragment purified by agarose gel and ligated into the vector pcDNA-3 (Invitrogen, San Diego, CA) prepared by digesting with the same enzymes. The resultant construct, 30 pcB7-2, was confirmed by restriction mapping and DNA sequence analysis using standard procedures.

A mouse B7-2 clone, pcmb7-2, was isolated in a similar manner by RT-PCR of RNA isolated from P388D1 cells using the 5' primer,

-57-

5'-GAT-CAG-GGT-ACC-AAG-AGT-GGC-TCC-TGT-AGG-CA  
(sense, SEQ ID NO: 99), and the 3' primer,

5'-GAT-AGC-CTC-GAG-GTA-GAA-TTC-CAA-TCA-GCT-GA  
(antisense, SEQ ID NO: 100).

5 The 5' primer has identity with bases 1-20, whereas  
the 3' primer is complementary to bases 1096-1115, of the  
published murine B7-2 sequence (Chen et al., *J. Immun.*,  
1994, 152, 4929). Both primers incorporate the respective  
restriction enzyme sites found in the other 5' and 3'  
10 primers used to prepare cDNA clones. The RT-PCR product  
was restricted with Xho I and Kpn I and ligated into pcDNA-  
3 (Invitrogen, San Diego, CA).

Other cDNA clones, corresponding to mRNAs resulting  
from alternative splicing events, are cloned in like  
15 fashion, using primers containing the appropriate  
restriction sites and having identity with (5' primers), or  
complementarity to (3' primers), the selected B7 mRNA.

**Example 2: Modulation of hB7-1 Expression by  
Oligonucleotides**

20 The ability of oligonucleotides to inhibit B7-1  
expression was evaluated by measuring the cell surface  
expression of B7-1 in transfected COS-7 cells by flow  
cytometry.

**Methods:**

25 A T-175 flask was seeded at 75% confluency with COS-7  
cells (ATCC accession No. CRL 1651). The plasmid pcB7-1  
was introduced into cells by standard calcium phosphate  
transfection. Following a 4 hour transfection, the cells  
were trypsinized and seeded in 12-well dishes at 80%  
30 confluency. The cells were allowed to adhere to the  
plastic for 1 hour and were then washed with phosphate-  
buffered saline (PBS). OptiMEM™ (GIBCO-BRL, Gaithersburg,  
MD) medium was added along with 15 µg/mL of Lipofectin™  
(GIBCO-BRL, Gaithersburg, MD) and oligonucleotide at the  
35 indicated concentrations. After four additional hours, the

-58-

cells were washed with phosphate buffered saline (PBS) and incubated with fresh oligonucleotide at the same concentration in DMEM (Dulbecco et al., Virol., 1959, 8, 396; Smith et al., Virol., 1960, 12, 185) with 10% fetal calf sera (FCS).

In order to monitor the effects of oligonucleotides on cell surface expression of B7-1, treated COS-7 cells were harvested by brief trypsinization 24-48 hours after oligonucleotide treatment. The cells were washed with PBS, 10 then resuspended in 100  $\mu$ L of staining buffer (PBS, 0.2% BSA, 0.1% azide) with 5  $\mu$ L conjugated anti-B7-1-antibody (i.e., anti-hCD80-FITC, Ancell, Bayport, MN; FITC: fluorescein isothiocyanate). The cells were stained for 30 minutes at 4°C, washed with PBS, resuspended in 300  $\mu$ L 15 containing 0.5% paraformaldehyde. Cells were harvested and the fluorescence profiles were determined using a flow cytometer.

**Results:**

The oligonucleotides shown in Table 1 were evaluated, 20 in COS-7 cells transiently expressing B7-1 cDNA, for their ability to inhibit B7-1 expression. The results (Figure 1) identified ISIS 13805, targeted to the translation initiation codon region, and ISIS 13812, targeted to the 3' untranslated region (UTR), as the most active 25 oligonucleotides with greater than 50% inhibition of B7-1 expression. These oligonucleotides are thus highly preferred. ISIS 13799 (targeted to the 5' untranslated region), ISIS 13802 (targeted to the 5' untranslated region), ISIS 13806 and 13807 (both targeted to the 5' 30 region of the ORF), and ISIS 13810 (targeted to the central portion of the ORF) demonstrated 35% to 50% inhibition of B7-1 expression. These sequences are therefore also preferred.

Oligonucleotide ISIS 13800, which showed essentially 35 no inhibition of B7-1 expression in the flow cytometry

-59-

assay, and ISIS Nos. 13805 and 13812 were then evaluated for their ability to inhibit cell surface expression of B7-1 at various concentrations of oligonucleotide. The results of these assays are shown in Figure 2. ISIS 13812 5 was a superior inhibitor of B7-1 expression with an IC<sub>50</sub> of approximately 150 nM. ISIS 13800, targeted to the 5' UTR, was essentially inactive.

**Example 3: Modulation of *hB7-2* Protein by Oligonucleotides**

10 In an initial screen, the ability of *hB7-2* oligonucleotides to inhibit B7-2 expression was evaluated by measuring the cell surface expression of B7-2 in transfected COS-7 cells by flow cytometry. The methods used were similar to those given in Example 2, with the 15 exceptions that (1) COS-7 cells were transfected with the plasmids pbcB7-2 or BBG-58, a human ICAM-1 (CD54) expression vector (R&D Systems, Minneapolis, MN) introduced into cells by standard calcium phosphate transfection, (2) the oligonucleotides used were those described in Table 2, 20 and (3) a conjugated anti-B7-2 antibody (i.e., anti-hCD86-FITC or anti-CD86-PE, PharMingen, San Diego, CA; PE: phycoerythrin) was used during flow cytometry.

**Results:**

The results are shown in Figure 3. At a concentration 25 of 200 nM, ISIS 9133, ISIS 9139 and ISIS 10373 exhibited inhibitory activity of 50% or better and are therefore highly preferred. These oligonucleotides are targeted to the 3' untranslated region (ISIS 9133), the translation initiation codon region (ISIS 9139) and the 5' untranslated 30 region (ISIS 10373). At the same concentration, ISIS 10715, ISIS 10716 and ISIS 10721, which are scrambled controls for ISIS 9133, ISIS 9139 and ISIS 10373, respectively, showed no inhibitory activity. Treatment with ISIS 10367 and ISIS 10369 resulted in greater than 25% 35 inhibition, and these oligonucleotides are thus also

- 60 -

preferred. These oligonucleotides are targeted to the 5' (ISIS 10367) and 3' (ISIS 10369) untranslated regions.

**Example 4: Modulation of hB7-2 mRNA by Oligonucleotides**

**Methods:**

5 For ribonuclease protection assays, cells were harvested 18 hours after completion of oligonucleotide treatment using a Totally RNA™ kit (Ambion, Austin, TX). The probes for the assay were generated from plasmids pcB7-2 (linearized by digestion with Bgl II) and pTRI-b-actin 10 (Ambion Inc., Austin, TX). *In vitro* transcription of the linearized plasmid from the SP6 promoter was performed in the presence of  $\alpha$ -<sup>32</sup>P-UTP (800 Ci/mmmole) yielding an antisense RNA complementary to the 3' end of B7-2 (position 1044-1391). The probe was gel-purified after treatment 15 with DNase I to remove DNA template. Ribonuclease protection assays were carried out using an RPA II™ kit (Ambion) according to the manufacturer's directions. Total RNA (5  $\mu$ g) was hybridized overnight, at 42°C, with 10<sup>5</sup> cpm of the B7-2 probe or a control beta-actin probe. The 20 hybridization reaction was then treated, at 37°C for 30 minutes, with 0.4 units of RNase A and 2 units of RNase T1. Protected RNA was precipitated, resuspended in 10  $\mu$ L of gel loading buffer and electrophoresed on a 6% acrylamide gel with 50% w/v urea at 20 W. The gel was then exposed and 25 the lanes quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) essentially according to the manufacturer's instructions.

**Results:**

The extent of oligonucleotide-mediated hB7-2 mRNA 30 modulation generally paralleled the effects seen for hB7-2 protein (Table 5). As with the protein expression (flow cytometry) assays, the most active oligonucleotides were ISIS 9133, ISIS 9139 and 10373. None of the 35 oligonucleotides tested had an inhibitory effect on the expression of b-actin mRNA in the same cells.

-61-

TABLE 5

## Activities of Oligonucleotides Targeted to hB7-2 mRNA

5	ISIS NO.	SEQ ID NO.	% Control Protein	% Control RNA Expression
9133	3		70.2	46.0
9134	4		88.8	94.5
9135	5		98.2	83.4
9136	6		97.1	103.1
10	9137	7	80.5	78.1
9138	8		86.4	65.9
9139	9		47.9	32.6
10367	10		71.3	52.5
10368	11		81.0	84.5
15	10369	12	71.3	81.5
10370	13		84.3	83.2
10371	14		97.3	92.9
10372	15		101.7	82.5
20	10373	16	43.5	32.7

Example 5: Additional hB7-1 and hB7-2 Oligonucleotides  
 Oligonucleotides having structures and/or sequences  
 that were modified relative to the oligonucleotides  
 identified during the initial screening were prepared.

25 These oligonucleotides were evaluated for their ability to  
 modulate human B7-2 expression using the methods described  
 in the previous Examples.

ISIS 10996, an oligonucleotide having a 15 nucleotide  
 sequence derived from the 20 nucleotide sequence of ISIS  
 30 10373, was also prepared and evaluated. ISIS 10996  
 comprises 15 nucleotides, 5'-GCG-AGC-TCC-CCG-TAC (SEQ ID  
 NO: 90) contained within the sequence of ISIS 10373. Both  
 ISIS 10373 and 10996 overlap a potential stem-loop  
 structure located within the B7-2 message comprising bases

-62-

1-67 of the sequence of *hB7-2* presented by Azuma et al. (*Nature*, 1993, 366, 76). While not intending to be bound by any particular theory regarding their mode(s) of action, ISIS 10373 and ISIS 10996 have the potential to bind as

5 loop 1 pseudo-half-knots at a secondary structure within the target RNA. U.S. Patent 5,5152,438, which issued April 30, 1996, the contents of which are hereby incorporated by reference, describes methods for modulating gene expression by the formation of pseudo-half-knots. Regardless of their

10 mode(s) of action, despite having a shorter length than ISIS 10373, the 15-mer ISIS 10996 is as (or more) active in the B7-2 protein expression assay than the 20-mer from which it is derived (Figure 4; ISIS 10721 is a scrambled control for ISIS 10373). A related 16-mer, ISIS 10889, was

15 also active in the B7-2 protein expression assay. However, a structurally related 14-mer (ISIS 10995), 13-mer (ISIS 10994), 12-mer (ISIS 10993), 11-mer (ISIS 10992) and 10-mer (ISIS 10991) exhibited little or no activity in this assay. ISIS 10996 was further derivatized in the following ways.

20 ISIS 10996 derivatives having 2' methoxethoxy substitutions were prepared, including a fully substituted derivative (ISIS 11539), "gapmers" (ISIS 11541 and 11543) and "wingmers" (ISIS 11545 and 11547). As explained in Example 5, the 2' methoxyethoxy substitution prevents the

25 action of some nucleases (e.g., RNase H) but enhances the affinity of the modified oligonucleotide for its target RNA molecule. These oligonucleotides are tested for their ability to modulate *hB7-2* message or function according to the methods of Examples 3, 4, 7 and 8.

30 ISIS 10996 derivatives were prepared in order to be evaluated for their ability to recruit RNase L to a target RNA molecule, e.g., *hB7-2* message. RNase L binds to, and is activated by, (2'-5')(A)<sub>n</sub>, which is in turn produced from ATP by (2'-5')(A)<sub>n</sub> synthetase upon activation by, e.g.,

-63-

interferon. RNase L has been implicated in antiviral mechanisms and in the regulation of cell growth as well (Sawai, *Chemica Scripta*, 1986, 21, 169; Charachon et al., *Biochemistry*, 1990, 29, 2550). The combination of anti-B7 5 oligonucleotides conjugated to (2'-5')(A)<sub>n</sub> is expected to result in the activation of RNase L and its targeting to the B7 message complementary to the oligonucleotide sequence. The following oligonucleotides have identical sequences (i.e., that of ISIS 10996) and identical (2'- 10 5')(A)<sub>4</sub> "caps" on their 5' termini: ISIS 12492, 12495, 12496 and 13107. The adenosyl residues have 3' hydroxyl groups and are linked to each other by phosphorothioate linkages. The (3'-5') portion of the oligonucleotide, which has a sequence complementary to a portion of the human B7-2 RNA, 15 is conjugated to the (2'-5')(A)<sub>4</sub> "cap" via a phosphorothioate linkage from the 5' residue of the (3'-5') portion of the oligonucleotide to an *n*-aminohexyl linker which is bonded to the "cap" via another phosphorothioate linkage. In order to test a variety of chemically diverse 20 oligonucleotides of this type for their ability to recruit RNase L to a specific message, different chemical modifications were made to this set of four oligonucleotides as follows. ISIS 12496 consists of unmodified oligonucleotides in the (3'-5') portion of the 25 oligonucleotide. In ISIS 13107, phosphorothioate linkages replace the phosphate linkages found in naturally occurring nucleic acids. Phosphorothioate linkages are also employed in ISIS 12492 and 12495, which additionally have 2'- methoxyethoxy substitutions. These oligonucleotides are 30 tested for their ability to modulate hB7-2 message or function according to the methods of Examples 3, 4, 7 and 8.

Derivatives of ISIS 10996 having modifications at the 2' position were prepared and evaluated. The modified

-64-

oligonucleotides included ISIS 11539 (fully 2'-O-methyl), ISIS 11541 (having 2'-O-methyl "wings" and a central 7-base "gap"), ISIS 11543 (2'-O-methyl wings with a 9-base gap), ISIS 11545 (having a 5' 2'-O-methyl wing) and ISIS 11547 5 (having a 3' 2'-O-methyl wing). The results of assays of 2'-O-methyl oligonucleotides were as follows. ISIS 11539, the fully 2'-O-methyl version of ISIS 10996, was not active at all in the protein expression assay. The gapped and winged oligonucleotides (ISIS 11541, 11543, 11545 and 10 11547) each showed some activity at 200 nM (i.e., from 60 to 70% expression relative to untreated cells), but less than that demonstrated by the parent compound, ISIS 10996 (i.e., about 50% expression). Similar results were seen in RNA expression assays.

15 ISIS 10782, a derivative of ISIS 10373 to which cholesterol has been conjugated via a 5' *n*-aminohexyl linker, was prepared. Lipophilic moieties such as cholesterol have been reported to enhance the uptake by cells of oligonucleotides in some instances, although the 20 extent to which uptake is enhanced, if any, remains unpredictable. ISIS 10782, and other oligonucleotides comprising lipophilic moieties, are tested for their ability to modulate B7-2 message or function according to the methods of Examples 3, 4, 7 and 8.

25 A series of 2'-methoxyethoxy (herein, "2'ME") and 2'-fluoride (herein, "2'F") "gapmer" derivatives of the *hB7-1* oligonucleotides ISIS 12361 (ISIS Nos. 12348 and 12473, respectively), ISIS 12362 (ISIS Nos. 12349 and 12474), ISIS 12363 (ISIS Nos. 12350 and 12475), ISIS 12364 (ISIS Nos. 30 12351 and 12476), ISIS 12365 (ISIS Nos. 12352 and 12477), ISIS 12366 (ISIS Nos. 12353 and 12478), ISIS 12367 (ISIS Nos. 12354 and 12479), ISIS 12368 (ISIS Nos. 12355 and 12480), ISIS 12369 (ISIS Nos. 12356 and 12481) and ISIS 12370 (ISIS Nos. 12357 and 12482) were prepared. The

-65-

central, non-2'-modified portions ("gaps") of these derivatives support RNase H activity when the oligonucleotide is bound to its target RNA, even though the 2'-modified portions do not. However, the 2'-modified 5 "wings" of these oligonucleotides enhance their affinity to their target RNA molecules (Cook, Chapter 9 *In: Antisense Research and Applications*, Crooke et al., eds., CRC Press, Boca Raton, 1993, pp. 171-172).

Another 2' modification is the introduction of a 10 methoxy (MO) group at this position. Like 2'ME- and 2'F-modified oligonucleotides, this modification prevents the action of RNase H on duplexes formed from such oligonucleotides and their target RNA molecules, but enhances the affinity of an oligonucleotide for its target 15 RNA molecule. ISIS 12914 and 12915 comprise sequences complementary to the 5' untranslated region of alternative *hB7-1* mRNA molecules, which arise from alternative splicing events of the primary *hB7-1* transcript. These oligonucleotides include 2' methoxy modifications, and the 20 enhanced target affinity resulting therefrom may allow for greater activity against alternatively spliced B7-1 mRNA molecules which may be present in low abundance in some tissues (Inobe et al., *J. Immun.*, 1996, 157, 582). Similarly, ISIS 13498 and 13499, which comprise antisense 25 sequences to other alternative *hB7-1* mRNAs, include 2' methoxyethoxy modifications in order to enhance their affinity for their target molecules, and 2' methoxyethoxy or 2' methoxy substitutions are incorporated into the *hB7-2* oligonucleotides ISIS 12912, 12913, 13496 and 13497. These 30 oligonucleotides are tested for their ability to modulate *hB7-1* essentially according to the methods of Example 2 or *hB7-2* according to the methods of Examples 3, 4, 7 and 8, with the exception that, when necessary, the target cells

-66-

are transfected with a cDNA clone corresponding to the appropriate alternatively spliced B7 transcript.

**Example 6: Specificity of Antisense Modulation**

Several oligonucleotides of the invention were evaluated in a cell surface expression flow cytometry assay to determine the specificity of the oligonucleotides for B7-1 as contrasted with activity against B7-2. The oligonucleotides tested in this assay included ISIS 13812, an inhibitor of B7-1 expression (Figure 1; Example 2) and ISIS 10373, an inhibitor of B7-2 expression (Figure 3; Example 3). The results of this assay are shown in Figure 5. ISIS 13812 inhibits B7-1 expression with little or no effect on B7-2 expression. As is also seen in Figure 5, ISIS 10373 inhibits B7-2 expression with little or no effect on B7-1 expression. ISIS 13872 (SEQ ID NO: 37, AGT-CCT-ACT-ACC-AGC-CGC-CT), a scrambled control of ISIS 13812, and ISIS 13809 (SEQ ID NO: 51) were included in these assays and demonstrated essentially no activity against either B7-1 or B7-2.

**20 Example 7: Modulation of hB7-2 Expression by Oligonucleotides in Antigen Presenting Cells**

The ability of ISIS 10373 to inhibit expression from the native B7-2 gene in antigen presenting cells (APCs) was evaluated as follows.

**25 Methods:**

Monocytes were cultured and treated with oligonucleotides as follows. For dendritic cells, EDTA-treated blood was layered onto Polymorphprep™ (1.113 g/mL; Nycomed, Oslo, Norway) and sedimented at 500x g for 30 minutes at 20°C. Mononuclear cells were harvested from the interface. Cells were washed with PBS, with serum-free RPMI media (Moore et al., N.Y. J. Med., 1968, 68, 2054) and then with RPMI containing 5% fetal bovine serum (FBS). Monocytes were selected by adherence to plastic cell

-67-

culture cell culture dishes for 1 h at 37°C. After adherence, cells were treated with oligonucleotides in serum-free RPMI containing Lipofectin™ (8 µg/mL). After 4 hours, the cells were washed. Then RPMI containing 5% FBS and oligonucleotide was added to cells along with interleukin-4 (IL-4; R&D Systems, Minneapolis, MN) (66 ng/mL) and granulocyte-macrophage colony-stimulating factor (GM-CSF; R&D Systems, Minneapolis, MN) (66 ng/mL) to stimulate differentiation (Romani et al., *J. Exp. Med.*, 1994, 180, 83, 1994). Cells were incubated for 48 hours, after which cell surface expression of various molecules was measured by flow cytometry.

Mononuclear cells isolated from fresh blood were treated with oligonucleotide in the presence of cationic lipid to promote cellular uptake. As a control oligonucleotide, ISIS 2302 (an inhibitor of ICAM-1 expression; SEQ ID NO: 17) was also administered to the cells. Expression of B7-2 protein was measured by flow cytometry according to the methods of Example 2.

Monoclonal antibodies not described in the previous Examples included anti-hCD3 (Ancell, Bayport, MN) and anti-HLA-DR (Becton Dickinson, San Jose, CA).

**Results:**

As shown in Figure 6, ISIS 10373 has a significant inhibitory effect on B7-2 expression with an IC<sub>50</sub> of approximately 250 nM. ISIS 10373 had only a slight effect on ICAM-1 expression even at a dose of 1 µM. ISIS 2302 (SEQ ID NO: 17), a control oligonucleotide which has been shown to inhibit ICAM-1 expression, had no effect on B7-2 expression, but significantly decreased ICAM-1 levels with an IC<sub>50</sub> of approximately 250 nM. Under similar conditions, ISIS 10373 did not affect the cell surface expression of B7-1, HLA-DR or CD3 as measured by flow cytometry.

**Example 8: Modulation of T Cell Proliferation by Oligonucleotides**

The ability of ISIS 2302 and ISIS 10373 to inhibit T cell proliferation was evaluated as follows. Monocytes 5 treated with oligonucleotide and cytokines (as in Example 6) were used as antigen presenting cells in a T cell proliferation assay. The differentiated monocytes were combined with CD4+ T cells from a separate donor. After 48 hours, proliferation was measured by [<sup>3</sup>H] thymidine 10 incorporation.

**Methods:**

For T cell proliferation assays, cells were isolated from EDTA-treated whole blood as described above, except that a faster migrating band containing the lymphocytes was 15 harvested from just below the interface. Cells were washed as described in Example 6 after which erythrocytes were removed by NH<sub>4</sub>Cl lysis. T cells were purified using a T cell enrichment column (R&D Systems, Minneapolis, MN) essentially according to the manufacturer's directions. 20 CD4+ T cells were further enriched from the entire T cell population by depletion of CD8+ cells with anti-CD8-conjugated magnetic beads (AMAC, Inc., Westbrook, ME) according to the manufacturer's directions. T cells were determined to be >80% CD4+ by flow cytometry using Cy-25 chrome-conjugated anti-CD4 mAb (PharMingen, San Diego, CA).

Antigen presenting cells (APCs) were isolated as described in Example 6 and treated with mitomycin C (25 µg/mL) for 1 hour then washed 3 times with PBS. APCs (10<sup>5</sup> cells) were then combined with 4 x 10<sup>4</sup> CD4+ T cells in 350 30 µL of culture media. Where indicated, purified CD3 mAb was also added at a concentration of 1 µg/mL. During the last 6 hours of the 48 hour incubation period, proliferation was measured by determining uptake of 1.5 uCi of [<sup>3</sup>H]-thymidine

-69-

per well. The cells were harvested onto filters and the radioactivity measured by scintillation counting.

**Results:**

As shown in Figure 7, mononuclear cells which were not 5 cytokine-treated slightly induced T cell proliferation, presumably due to low levels of costimulatory molecules expressed on the cells. However, when the cells were treated with cytokines and induced to differentiate to dendritic-like cells, expression of both ICAM-1 and B7-2 10 was strongly upregulated. This resulted in a strong T cell proliferative response which could be blocked with either anti-ICAM-1 (ISIS 2302) or anti-B7-2 (ISIS 10373) oligonucleotides prior to induction of the mononuclear cells. The control oligonucleotide (ISIS 10721) had an 15 insignificant effect on T cell proliferation. A combination treatment with both the anti-ICAM-1 (ISIS 2302) and anti-B7-2 (ISIS 10373) oligonucleotides resulted in a further decrease in T cell response.

**Example 9: Modulation of Murine B7 Genes by 20 Oligonucleotides**

Oligonucleotides (see Table 4) capable of inhibiting expression of murine B7-2 transiently expressed in COS-7 cells were identified in the following manner. A series of phosphorothioate oligonucleotides complementary to murine 25 B7-2 (mB7-2) cDNA were screened for their ability to reduce mB7-2 levels (measured by flow cytometry as in Example 2, except that a conjugated anti-mB7-2 antibody (i.e., anti-mCD86-PE, PharMingen, San Diego, CA) in COS-7 cells ~~transfected with an mB7-2 cDNA clone. Anti-mB7-2 antibody~~  
30 may also be obtained from the hybridoma deposited at the ATCC under accession No. HB-253. Oligonucleotides (see Table 2) capable of modulating murine B7-1 expression are isolated in like fashion, except that a conjugated anti-

- 70 -

mB7-1 antibody is used in conjunction with COS-7 cells transfected with an mB7-1 cDNA clone.

For murine B7-2, the most active oligonucleotide identified was ISIS 11696 (GGA-TTG-CCA-AGC-CCA-TGG-TG, SEQ 5 ID NO: 18), which is complementary to position 96-115 of the cDNA, a site which includes the translation initiation (AUG) codon. Figure 8 shows a dose-response curve for ISIS 11696 and a scrambled control, ISIS 11866 (CTA-AGT-AGT-GCT-AGC-CGG-GA, SEQ ID NO: 19). ISIS 11696 inhibited cell 10 surface expression of B7-2 in COS-7 cells with an IC<sub>50</sub> in the range of 200-300 nM, while ISIS 11866 exhibited less than 20% inhibition at the highest concentration tested (1000 nM).

In order to further evaluate the murine B7-2 antisense 15 oligonucleotides, the IC-21 cell line was used. IC-21 monocyte/macrophage cell line expresses both B7-1 and murine B7-2 (mB7-2) constitutively. A 2-fold induction of expression can be achieved by incubating the cells in the presence of lipopolysaccharide (LPS; GIBCO-BRL, 20 Gaithersburg, MD) (Hathcock et al., *Science*, 1993, 262, 905).

IC-21 cells (ATCC; accession No. TIB 186) were seeded at 80% confluence in 12-well plates in DMEM media with 10% FCS. The cells were allowed to adhere to the plate 25 overnight. The following day, the medium was removed and the cells were washed with PBS. Then 500  $\mu$ L of OptiMEM<sup>TM</sup> (GIBCO-BRL, Gaithersburg, MD) supplemented with 15  $\mu$ g/mL of Lipofectin<sup>TM</sup> (GIBCO-BRL, Gaithersburg, MD) was added to each well. Oligonucleotides were then added directly to the 30 medium at the indicated concentrations. After incubation for 4 hours, the cells were washed with PBS and incubated overnight in culture medium supplemented with 15  $\mu$ g/mL of LPS. The following day, cells were harvested by scraping,

- 71 -

then analyzed for cell surface expression by flow cytometry.

ISIS 11696 and ISIS 11866 were administered to IC-21 cells in the presence of Lipofectin™ (GIBCO-BRL, Gaithersburg, 5 MD). The results are shown in Figure 9. At a concentration of 10 uM, ISIS 11696 inhibited mB7-2 expression completely (and decreased mB7-2 levels below the constitutive level of expression), while the scrambled control oligonucleotide, ISIS 11866, produced only a 40% 10 reduction in the level of induced expression. At a concentration of 3 uM, levels of induced expression were greatly reduced by ISIS 11696, while ISIS 11866 had little effect.

Modified oligonucleotides, comprising 2' substitutions 15 (e.g., 2' methoxy, 2' methoxyethoxy) and targeted to alternative transcripts of murine B7-1 (ISIS 12914, 12915, 13498, 13499) or murine B7-2 (ISIS 13100, 13100 and 13102) were prepared. These oligonucleotides are tested for their ability to modulate murine B7 essentially according to the 20 above methods using IC-21 cells or COS-7 transfected with a cDNA clone corresponding to the appropriate alternatively spliced B7 transcript.

**Example 10: Modulation of Allograft Rejection by Oligonucleotides**

25 A murine model for evaluating compounds for their ability to inhibit heart allograft rejection has been previously described (Stepkowski et al., *J. Immunol.*, 1994, 153, 5336). This model was used to evaluate the immunosuppressive capacity of antisense oligonucleotides to  
30 B7 proteins alone or in combination with antisense oligonucleotides to intercellular adhesion molecule-1 (ICAM-1).

**Methods:**

Heart allograft rejection studies and oligonucleotide

-72-

treatments of BALB/c mice were performed essentially as previously described (Stepkowski et al., *J. Immunol.*, 1994, 153, 5336). Antisense oligonucleotides used included ISIS 11696, ISIS 3082 (targeted to ICAM-1) and ISIS 1082 (a 5 control oligonucleotide targeted to the herpes virus UL-13 gene sequence). Dosages used were 1, 2, 2.5, 5 or 10 mg/kg of individual oligonucleotide (as indicated below); when combinations of oligonucleotides were administered, each oligonucleotide was given at a dosage of 1, 5 or 10 mg/kg 10 (total oligonucleotide dosages of 2, 10 and 20 mg/kg, respectively). The survival times of the transplanted hearts and their hosts were monitored and recorded.

**Results:**

The mean survival time for untreated mice was  $8.2 \pm$  15 0.8 days (7,8,8,8,9,9 days). Treatment of the mice for 7 days with ISIS 1082 (SEQ ID NO: 125, unrelated control oligonucleotide) slightly reduced the mean survival times to  $7.1 \pm 0.7$  days (5 mg/kg/day; 6,7,7,7,8,8) or  $7.0 \pm 0.8$  days (10 mg/kg/day; 6,7,7,8). Treatment of the mice for 20 seven days with the murine B7-2 oligonucleotide ISIS 11696 (SEQ ID NO: 108) increased the mean survival time to 9.3 days at two doses (2 mg/kg/day,  $9.3 \pm 0.6$  days, 9,9,10; 10 mg/kg/day,  $9.3 \pm 1.3$  days, 8,9,9,11). Treatment of mice for seven days with an ICAM-1 oligonucleotide, ISIS 3082, 25 also increased the mean survival of the mice over several doses. Specifically, at 1 mg/kg/day, the mean survival time (MSD) was  $11.0 \pm 0.0$  (11,11,11); at 2.5 mg/kg/day, the MSD was  $12.0 \pm 2.7$  (10,12,13,16); at 5 mg/kg/day, the MSD was  $14.1 \pm 2.7$  (10,12,12,13,16,16,17,17); and, at 10 mg/kg/day, the MSD was  $15.3 \pm 5.8$  (12,12,13,24). Some 30 synergistic effect was seen when the mice were treated for seven days with 1 mg/kg/day each of ISIS 3082 and 11696: the MSD was  $13.8 \pm 1.0$  (13,13,14,15).

-73-

**Example 11: Detection of Nucleic Acids Encoding B7 Proteins**

Oligonucleotides are radiolabeled after synthesis by  $^{32}\text{P}$ -labeling at the 5' end with polynucleotide kinase.

5 Sambrook et al., "Molecular Cloning. A Laboratory Manual," Cold Spring Harbor Laboratory Press, 1989, Volume 2, pg. 11.31. Radiolabeled oligonucleotide capable of hybridizing to a nucleic acid encoding a B7 protein is contacted with a tissue or cell sample suspected of B7 protein expression 10 under conditions in which specific hybridization can occur, and the sample is washed to remove unbound oligonucleotide. A similar control is maintained wherein the radiolabeled oligonucleotide is contacted with a normal tissue or cell sample under conditions that allow specific hybridization, 15 and the sample is washed to remove unbound oligonucleotide. Radioactivity remaining in the samples indicates bound oligonucleotide and is quantitated using a scintillation counter or other routine means. A greater amount of radioactivity remaining in the samples, as compared to 20 control tissues or cells, indicates increased expression of a B7 gene, whereas a lesser amount of radioactivity in the samples relative to the controls indicates decreased expression of a B7 gene.

Radiolabeled oligonucleotides of the invention are 25 also useful in autoradiography. A section of tissues suspected of expressing a B7 gene is treated with radiolabeled oligonucleotide and washed as described above, then exposed to photographic emulsion according to standard autoradiography procedures. A control of a normal tissue 30 section is also maintained. The emulsion, when developed, yields an image of silver grains over the regions expressing a B7 gene, which is quantitated. The extent of B7 expression is determined by comparison of the silver grains observed with control and test samples.

-74-

Analogous assays for fluorescent detection of expression of a B7 gene use oligonucleotides of the invention which are labeled with fluorescein or other fluorescent tags. Labeled oligonucleotides are synthesized 5 on an automated DNA synthesizer (Applied Biosystems, Foster City, CA) using standard phosphoramidite chemistry. b-Cyanoethyldiisopropyl phosphoramidites are purchased from Applied Biosystems (Foster City, CA). Fluorescein-labeled amidites are purchased from Glen Research (Sterling, VA). 10 Incubation of oligonucleotide and biological sample is carried out as described above for radiolabeled oligonucleotides except that, instead of a scintillation counter, a fluorescence microscope is used to detect the fluorescence. A greater amount of fluorescence in the 15 samples, as compared to control tissues or cells, indicates increased expression of a B7 gene, whereas a lesser amount of fluorescence in the samples relative to the controls indicates decreased expression of a B7 gene.

**Example 12: Chimeric (deoxy gapped) Human B7-1 Antisense 20 Oligonucleotides**

Additional oligonucleotides targeting human B7-1 were synthesized. Oligonucleotides were synthesized as uniformly phosphorothioate chimeric oligonucleotides having regions of five 2'-O-methoxyethyl (2'-MOE) nucleotides at 25 the wings and a central region of ten deoxynucleotides. Oligonucleotide sequences are shown in Table 6.

Oligonucleotides were screened as described in Example 4. Results are shown in Table 7.

Oligonucleotides 22315 (SEQ ID NO: 128), 22316 (SEQ ID 30 NO: 26), 22317 (SEQ ID NO: 129), 22320 (SEQ ID NO: 132), 22324 (SEQ ID NO: 135), 22325 (SEQ ID NO: 136), 22334 (SEQ ID NO: 145), 22335 (SEQ ID NO: 146), 22337 (SEQ ID NO: 148), and 22338 (SEQ ID NO: 36) resulted in 50% or greater inhibition of B7-1 mRNA in this assay.

-75-

TABLE 6:

Nucleotide Sequences of Human B7-1 Chimeric (deoxy gapped)  
Oligodeoxynucleotides

5	ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
			NO:		
	22313	AGACTCCACTTCTGAGATGT	126	0048-0067	5'-UTR
	22314	TGAAGAAAAATTCCACTTTT	127	0094-0113	5'-UTR
	22315	TTTAGTTCACAGCTTGCTG	128	0112-0129	5'-UTR
10	22316	GCTCACGTAGAACGACCCCTCC	26	0193-0212	5'-UTR
	22317	TCCCAGGTGCAAAACAGGCA	129	0233-0252	5'-UTR
	22318	GTGAAAGCCAACAATTGGA	130	0274-0293	5'-UTR
	22319	CATGGCTTCAGATGCTTAGG	131	0301-0320	AUG
	22320	TTGAGGTATGGACACTTGGAA	132	0351-0370	coding
15	22321	GACCAGCCAGCACCAAGAGC	31	0380-0399	coding
	22322	GCGTGTCCACTTCTTCACT	133	0440-0459	coding
	22323	TTTGCCAGTAGATGCGAGT	134	0501-0520	coding
	22324	GGCCATATATTATGTCCCC	135	0552-0571	coding
	22325	GCCAGGATCACAATGGAGAG	136	0612-0631	coding
20	22326	GTATGTGCCCTCGTCAGATG	137	0640-0659	coding
	22327	TTCAGCCAGGTGTTCCCGCT	138	0697-0716	coding
	22328	GGAAGTCAGCTTGACTGAT	139	0725-0744	coding
	22329	CCTCCAGAGGTTGAGCAAAT	140	0798-0817	coding
	22330	CCAACCAGGAGAGGTGAGGC	141	0827-0846	coding
25	22331	GAAGCTGTGGTTGGTTGTCA	142	0940-0959	coding
	22332	TTGAAGGTCTGATTCACTCT	143	0987-1006	coding

-76-

22333	<b>AAGGTAATGGCCCAGGATGG</b>	144	1050-1069	coding
22334	<b>AAGCAGTAGGTCAAGCAGCA</b>	145	1098-1117	coding
22335	<b>CCTTGCTTCTGCGGACACTG</b>	146	1185-1204	3'-UTR
22336	<b>AGCCCCTTGCTTCTGCGGAC</b>	147	1189-1208	3'-UTR
5	<b>TGACGGAGGCTACCTTCAGA</b>	148	1216-1235	3'-UTR
	<b>GCCTCATGATCCCCACGATC</b>	149	1254-1273	3'-UTR
	<b>GTAAAACAGCTTAAATTGT</b>	150	1286-1305	3'-UTR
	<b>AGAAGAGGTTACATTAAGCA</b>	151	1398-1417	3'-UTR
10	<b>AGATAATGAATTGGCTGACA</b>	152	control	
	<b>GCGTCATCATCCGCACCATC</b>	153	control	
	<b>CGTTGCTTGTGCCGACAGTG</b>	154	control	
	<b>GCTCACGAAGAACACCTTCC</b>			

<sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues (others are 2'-deoxy-). All 2'-methoxyethyl cytosines and 2'-deoxy cytosines residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

<sup>2</sup>Co-ordinates from Genbank Accession No. M27533, locus name "HUMIGB7".

TABLE 7

Inhibition of Human B7-1 mRNA Expression by Chimeric (deoxy gapped) Phosphorothioate Oligodeoxynucleotides

ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
basal	---	---	100%	---
13805	30	AUG	46%	54%

- 77 -

	13812	36	3'-UTR	22%	78%
	22313	126	5'-UTR	75%	25%
	22314	127	5'-UTR	69%	31%
	22315	128	5'-UTR	49%	51%
5	22316	26	5'-UTR	42%	58%
	22317	129	5'-UTR	43%	57%
	22318	130	5'-UTR	63%	37%
	22319	131	AUG	68%	32%
	22320	132	coding	45%	55%
10	22321	31	coding	57%	43%
	22324	135	coding	46%	54%
	22325	136	coding	46%	54%
	22326	137	coding	62%	38%
	22328	139	coding	64%	36%
15	22329	140	coding	59%	41%
	22330	141	coding	54%	46%
	22331	142	coding	62%	38%
	22332	143	coding	67%	33%
	22333	144	coding	73%	27%
20	22334	145	coding	43%	57%
	22335	146	3'-UTR	43%	57%
	22336	147	3'-UTR	55%	45%
	22337	148	3'-UTR	42%	58%
	22338	36	3'-UTR	40%	60%
25	22339	149	3'-UTR	69%	31%
	22340	150	3'-UTR	71%	29%

- 78 -

22341	151	3'-UTR	59%	41%
-------	-----	--------	-----	-----

Dose response experiments were performed on several of the more active oligonucleotides. The oligonucleotides were 5 screened as described in Example 4 except that the concentration of oligonucleotide was varied as shown in Table 8. Mismatch control oligonucleotides were included. Results are shown in Table 8.

All antisense oligonucleotides tested showed a dose 10 response effect with inhibition of mRNA approximately 60% or greater.

TABLE 8  
Dose Response of COS-7 Cells to B7-1  
Chimeric (deoxy gapped) Antisense Oligonucleotides

15	ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% mRNA Expression	% mRNA Inhibition
	basal	---	---	---	100%	---
20	22316	26	5'-UTR	10 nM	99%	1%
	"	"	"	30 nM	73%	27%
	"	"	"	100 nM	58%	42%
	"	"	"	300 nM	33%	67%
25	24735	154	control	10 nM	100%	---
	"	"	"	30 nM	95%	5%
	"	"	"	100 nM	81%	19%
	"	"	"	300 nM	75%	25%
	22335	146	3'-UTR	10 nM	81%	19%
	"	"	"	30 nM	63%	37%
	"	"	"	100 nM	43%	57%

- 79 -

			300 nM	35%	65%
5	24734	153	control	10 nM	94%
	"	"	"	30 nM	96%
	"	"	"	100 nM	94%
	"	"	"	300 nM	84%
	22338	36	3'-UTR	10 nM	68%
	"	"	"	30 nM	60%
	"	"	"	100 nM	53%
	"	"	"	300 nM	41%
10	24733	152	control	10 nM	90%
	"	"	"	30 nM	91%
	"	"	"	100 nM	90%
	"	"	"	300 nM	80%

15 Example 13: Chimeric (deoxy gapped) Mouse B7-1 Antisense Oligonucleotides

Additional oligonucleotides targeting mouse B7-1 were synthesized. Oligonucleotides were synthesized as uniformly phosphorothioate chimeric oligonucleotides having 20 regions of five 2'-O-methoxyethyl (2'-MOE) nucleotides at the wings and a central region of ten deoxynucleotides. Oligonucleotide sequences are shown in Table 9.

Oligonucleotides were screened as described in Example 4. Results are shown in Table 10.

25 Oligonucleotides 18105 (SEQ ID NO: 156), 18106 (SEQ ID NO: 157), 18109 (SEQ ID NO: 160), 18110 (SEQ ID NO: 161), 18111 (SEQ ID NO: 162), 18112 (SEQ ID NO: 163), 18113 (SEQ ID NO: 164), 18114 (SEQ ID NO: 165), 18115 (SEQ ID NO: 166), 18117 (SEQ ID NO: 168), 18118 (SEQ ID NO: 169), 18119 30 (SEQ ID NO: 170), 18120 (SEQ ID NO: 171), 18122 (SEQ ID NO:

-80-

173), and 18123 (SEQ ID NO: 174) resulted in greater than approximately 50% inhibition of B7-1 mRNA in this assay.

TABLE 9:

## Nucleotide Sequences of Mouse B7-1 Chimeric (deoxy gapped)

5

## Oligodeoxynucleotides

ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
18104	AGAGAAACTAGTAAGAGTCT	155	0018-0037	5'-UTR
18105	TGGCATCCACCCGGCAGATG	156	0110-0129	5'-UTR
18106	TCGAGAACAGAGATGTAGA	157	0144-0163	5'-UTR
18107	TGGAGCTTAGGCACCTCCTA	158	0176-0195	5'-UTR
18108	TGGGGAAAGCCAGGAATCTA	159	0203-0222	5'-UTR
18109	CAGCACAAAGAGAAGAATGA	160	0310-0329	coding
18110	ATGAGGAGAGTTGTAACGGC	161	0409-0428	coding
18111	AAGTCCGGTTCTTATACTCG	162	0515-0534	coding
18112	GCAGGTAATCCTTTAGTGT	163	0724-0743	coding
18113	GTGAAGTCCTCTGACACGTG	164	0927-0946	coding
18114	CGAATCCTGCCCAAAGAGC	165	0995-1014	coding
18115	ACTGCGCCGAATCCTGCC	166	1002-1021	coding
18116	TTGATGATGACAACGATGAC	167	1035-1054	coding
18117	CTGTTTTGTTCTGTGCT	168	1098-1117	coding
18118	TGTTCAGCTAATGCTTCTTC	169	1134-1153	coding
18119	GTAACTCTATCTGTGTCA	170	1263-1282	3'-UTR
18120	TCCACTTCAGTCATCAAGCA	171	1355-1374	3'-UTR
18121	TGCTCAATACTCTTTTA	172	1680-1699	3'-UTR

-81-

18122	AGGCCAGCAAACCTGCCG	173	1330-1349	3'-UTR
18123	AACGGCAAGGCAGCAATACC	174	0395-0414	coding

<sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues (others  
 5 are 2'-deoxy-). All 2'-methoxyethyl cytosines and 2'-deoxy  
 cytosines residues are 5-methyl-cytosines; all linkages are  
 phosphorothioate linkages.

<sup>2</sup>Co-ordinates from Genbank Accession No. X60958, locus name  
 "MMB7BLAA".

10

TABLE 10

Inhibition of Mouse B7-1 mRNA Expression by Chimeric (deoxy  
 gapped) Phosphorothioate Oligodeoxynucleotides

	ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
15	basal	---	---	100.0%	---
	18104	155	5'-UTR	60.0%	40.0%
	18105	156	5'-UTR	32.0%	68.0%
	18106	157	5'-UTR	51.0%	49.0%
	18107	158	5'-UTR	58.0%	42.0%
	18108	159	5'-UTR	82.0%	18.0%
	18109	160	coding	45.5%	54.5%
	18110	161	coding	21.0%	79.0%
	18111	162	coding	38.0%	62.0%
	18112	163	coding	42.0%	58.0%
25	18113	164	coding	24.6%	75.4%
	18114	165	coding	25.6%	74.4%
	18115	166	coding	33.5%	66.5%

18116	167	coding	65.6%	34.4%
18117	168	coding	46.7%	53.3%
18118	169	coding	31.7%	68.3%
18119	170	3'-UTR	24.0%	76.0%
5	18120	171	3'-UTR	26.7%
	18121	172	3'-UTR	114.0%
	18122	173	3'-UTR	42.0%
	18123	174	coding	42.0%
				58.0%

10 Example 14: Chimeric (deoxy gapped) Human B7-2 Antisense  
Oligonucleotides

Additional oligonucleotides targeting human B7-2 were synthesized. Oligonucleotides were synthesized as uniformly phosphorothioate chimeric oligonucleotides having regions of 15 five 2'-O-methoxyethyl (2'-MOE) nucleotides at the wings and a central region of ten deoxynucleotides. Oligonucleotide sequences are shown in Table 11.

Oligonucleotides were screened as described in Example 4. Results are shown in Table 12.

20 Oligonucleotides 22284 (SEQ ID NO: 16), 22286 (SEQ ID NO: 176), 22287 (SEQ ID NO: 177), 22288 (SEQ ID NO: 178), 22289 (SEQ ID NO: 179), 22290 (SEQ ID NO: 180), 22291 (SEQ ID NO: 181), 22292 (SEQ ID NO: 182), 22293 (SEQ ID NO: 183), 22294 (SEQ ID NO: 184), 22296 (SEQ ID NO: 186), 22299 (SEQ ID NO: 189), 22300 (SEQ ID NO: 190), 22301 (SEQ ID NO: 191), 22302 (SEQ ID NO: 192), 22303 (SEQ ID NO: 193), 22304 (SEQ ID NO: 194), 22306 (SEQ ID NO: 196), 22307 (SEQ ID NO: 197), 22308 (SEQ ID NO: 198), 22309 (SEQ ID NO: 199), 22310 (SEQ ID NO: 200), and 22311 (SEQ ID NO: 201) resulted in greater than 50% 30 inhibition of B7-2 mRNA in this assay.

-83-

TABLE 11:

Nucleotide Sequences of Human B7-2 Chimeric (deoxy gapped)  
Oligodeoxynucleotides

	ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
5	22284	TGCGAGCTCCCGTACCTCC	16	0011-0030	5'-UTR
	22285	CAGAAGCAAGGTGGTAAGAA	175	0049-0068	5'-UTR
	22286	GCCTGTCCACTGTAGCTCCA	176	0113-0132	5'-UTR
	22287	AGAATGTTACTCAGTCCCAT	177	0148-0167	AUG
	22288	TCAGAGGAGCAGCACCAAGAG	178	0189-0208	coding
	22289	TGGCATGGCAGGTCTGCAGT	179	0232-0251	coding
	22290	AGCTCACTCAGGCTTGGTT	180	0268-0287	coding
	22291	TGCCTAAGTATAACCTCATTC	181	0324-0343	coding
	22292	CTGTCAAATTCCTTTGCC	182	0340-0359	coding
	22293	CATATACTTGGAAATGAACAC	183	0359-0378	coding
	22294	GGTCCAACGTGCCGAATCAA	184	0392-0411	coding
	22295	TGATCTGAAGATTGTGAAGT	185	0417-0436	coding
	22296	AAGCCCTTGTCCCTTGATCTG	186	0430-0449	coding
	22297	TGTGATGGATGATACATTGA	187	0453-0472	coding
20	22298	TCAGGTTGACTGAAGTTAGC	188	0529-0548	coding
	22299	GTGTATAGATGAGCAGGTCA	189	0593-0612	coding
	22300	TCTGTGACATTATCTTGAGA	190	0694-0713	coding
	22301	AAGATAAAAGCCGCGTCTTG	191	0798-0817	coding
	22302	AGAAAACCATCACACATATA	192	0900-0919	coding

-84-

22303	<b>AGAGTTGCGAGGCCGCTTCT</b>	193	0947-0968	coding
22304	<b>TCCCTCTCCATTGTGTTGGT</b>	194	0979-0998	coding
22305	<b>CATCAGATCTTCAGGTATA</b>	195	1035-1054	coding
22306	<b>GGCTTTACTCTTAATTAAA</b>	196	1115-1134	stop
5	<b>GAAATCAAAAGGTTGCCA</b>	197	1178-1197	3'-UTR
	<b>GGAGTCCTGGAGCCCCCTTA</b>	198	1231-1250	3'-UTR
	<b>TTGGCATA CGGAGCAGAGCT</b>	199	1281-1300	3'-UTR
	<b>TGTGCTCTGAAGTGAAAAGA</b>	200	1327-1346	3'-UTR
	<b>GGCTTGGCCCATAAGTGTGC</b>	201	1342-1361	3'-UTR
10	<b>CCTAAATTTATTCAGGT</b>	202	1379-1398	3'-UTR
	<b>GCTCCAAGTGTCCCAATGAA</b>	203	control	
	<b>AGTATGTTCTCACTCCGAT</b>	204	control	
	<b>TGCCAGCACCCGGTACGTCC</b>	205	control	

15 <sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues (others are 2'-deoxy-). All 2'-methoxyethyl cytosines and 2'-deoxy cytosines residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

20 <sup>2</sup>Co-ordinates from Genbank Accession No. U04343 locus name "HSU04343".

TABLE 12

**Inhibition of Human B7-2 mRNA Expression by Chimeric (deoxy gapped) Phosphorothioate Oligodeoxynucleotides**

25	ISIS	SEQ ID	GENE	% mRNA	% mRNA
	No:	NO:	TARGET REGION	EXPRESSION	INHIBITION
	basal	---	---	100%	0%

-85-

	10373	16	5'-UTR	24%	76%
5	22284	16	5'-UTR	30%	70%
	22285	175	5'-UTR	74%	26%
	22286	176	5'-UTR	39%	61%
	22287	177	AUG	27%	73%
	22288	178	coding	38%	62%
	22289	179	coding	41%	59%
	22290	180	coding	42%	58%
10	22291	181	coding	41%	59%
	22292	182	coding	39%	61%
	22293	183	coding	43%	57%
	22294	184	coding	21%	79%
	22295	185	coding	66%	34%
	22296	186	coding	42%	58%
15	22297	187	coding	54%	46%
	22298	188	coding	53%	47%
	22299	189	coding	46%	54%
	22300	190	coding	39%	61%
	22301	191	coding	51%	49%
20	22302	192	coding	41%	59%
	22303	193	coding	46%	54%
	22304	194	coding	41%	59%
	22305	195	coding	57%	43%
25	22306	196	stop	44%	56%
	22307	197	3'-UTR	45%	55%
	22308	198	3'-UTR	40%	60%

- 86 -

22309	199	3'-UTR	42%	58%
22310	200	3'-UTR	41%	59%
22311	201	3'-UTR	49%	51%
22312	202	3'-UTR	83%	17%

5

Dose response experiments were performed on several of the more active oligonucleotides. The oligonucleotides were screened as described in Example 4 except that the concentration of oligonucleotide was varied as shown in Table 10 13. Mismatch control oligonucleotides were included. Results are shown in Table 13.

All antisense oligonucleotides tested showed a dose response effect with maximum inhibition of mRNA approximately 50% or greater.

15

TABLE 13

Dose Response of COS-7 Cells to B7-2  
Chimeric (deoxy gapped) Antisense Oligonucleotides

	SEQ ID ISIS #	ASO Gene Target	Dose	% mRNA Expression	% mRNA Inhibition
20	basal	---	---	100%	---
	22284	5'-UTR	10 nM	92%	8%
	"	"	30 nM	72%	28%
	"	"	100 nM	59%	41%
	"	"	300 nM	48%	52%
25	24738	control	10 nM	81%	19%
	"	"	30 nM	92%	8%
	"	"	100 nM	101%	---
	"	"	300 nM	124%	---
	22287	AUG	10 nM	93%	7%

-87-

	"	"	"	30 nM	79%	21%
	"	"	"	100 nM	66%	34%
	"	"	"	300 nM	45%	55%
	24737	204	control	10 nM	85%	15%
5	"	"	"	30 nM	95%	5%
	"	"	"	100 nM	87%	13%
	"	"	"	300 nM	99%	1%
	22294	184	coding	10 nM	93%	7%
	"	"	"	30 nM	95%	5%
	"	"	"	100 nM	58%	42%
10	"	"	"	300 nM	45%	55%
	24736	203	control	10 nM	102%	---
	"	"	"	30 nM	101%	---
	"	"	"	100 nM	100%	---
	15	"	"	300 nM	107%	---

**Example 15: Chimeric (deoxy gapped) Mouse B7-2 Antisense Oligonucleotides**

Additional oligonucleotides targeting mouse B7-2 were synthesized. Oligonucleotides were synthesized as uniformly phosphorothioate chimeric oligonucleotides having regions of five 2'-O-methoxyethyl (2'-MOE) nucleotides at the wings and a central region of ten deoxynucleotides. Oligonucleotide sequences are shown in Table 14.

25 Oligonucleotides were screened as described in Example

4. Results are shown in Table 15.

Oligonucleotides 18084 (SEQ ID NO: 206), 18085 (SEQ ID NO: 207), 18086 (SEQ ID NO: 208), 18087 (SEQ ID NO: 209), 18089 (SEQ ID NO: 211), 18090 (SEQ ID NO: 212), 18091 (SEQ ID NO: 213), 18093 (SEQ ID NO: 215), 18095 (SEQ ID NO: 217),

- 88 -

18096 (SEQ ID NO: 218), 18097 (SEQ ID NO: 219), 18098 (SEQ ID NO: 108), 18102 (SEQ ID NO: 223), and 18103 (SEQ ID NO: 224) resulted in 50% or greater inhibition of B7-2 mRNA expression in this assay.

5

TABLE 14:

Nucleotide Sequences of Mouse B7-2 Chimeric (deoxy gapped)  
Oligodeoxynucleotides

	ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
10	18084	GCTGCCTACAGGAGGCCACTC	206	0003-0022	5'-UTR
	18085	TCAAGTCCTGCTGCCTACA	207	0013-0032	5'-UTR
	18086	GTCTACAGGAGTCTGGTTGT	208	0033-0052	5'-UTR
	18087	AGCTTGCCTCTCCACGGAAA	209	0152-0171	coding
	18088	TCACACTATCAAGTTCTCT	210	0297-0316	coding
	18089	GTCAAAGCTCGTGCAGGCCA	211	0329-0348	coding
	18090	GTGAAGTCGTAGAGTCAGT	212	0356-0375	coding
	18091	GTGACCTTGCTTAGACGTGC	213	0551-0570	coding
	18092	CATCTTCTTAGGTTCGGGT	214	0569-0588	coding
	18093	GGCTGTTGGAGATACTGAAC	215	0663-0682	coding
	18094	GGGAATGAAAGAGAGAGGCT	216	0679-0698	coding
	18095	ACATACAATGATGAGCAGCA	217	0854-0873	coding
	18096	GTCTCTCTGTCAGCGTTACT	218	0934-0953	coding
	18097	TGCCAAGCCCATGGTGCATC	219	0092-0111	AUG
25	18098	GGATTGCCAAGCCCATGGTG	108	0096-0115	AUG
	18099	GCAATTGGGGTTCAAGTTC	220	0967-0986	coding

-89-

18100	<b>CAATCAGCTGAGAACATT</b> TT	221	1087-1106	3'-UTR
18101	<b>TTTTGTATAAAACAATCATA</b>	222	0403-0422	coding
18102	<b>CCTTCACTCTGCATTGGTT</b>	223	0995-1014	stop
18103	<b>TGCATGTTATCACCATACTC</b>	224	0616-0635	coding

5

<sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues (others are 2'-deoxy-). All 2'-methoxyethyl cytosines and 2'-deoxy cytosines residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

10

<sup>2</sup>Co-ordinates from Genbank Accession No. S70108 locus name "S70108".

TABLE 15

15 Inhibition of Mouse B7-2 mRNA Expression by Chimeric (deoxy gapped) Phosphorothioate Oligodeoxynucleotides

ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
basal	---	---	100.0%	0.0%
18084	206	5'-UTR	36.4%	63.6%
20	18085	207	35.0%	65.0%
	18086	208	40.1%	59.9%
	18087	209	42.1%	57.9%
	18088	210	52.3%	47.7%
	18089	211	20.9%	79.1%
25	18090	212	36.6%	63.4%
	18091	213	37.1%	62.9%
	18092	214	58.9%	41.1%

- 90 -

	18093	215	coding	32.7%	67.3%
	18094	216	coding	63.8%	36.2%
	18095	217	coding	34.3%	65.7%
	18096	218	coding	32.3%	67.7%
5	18097	219	AUG	24.5%	75.5%
	18098	108	AUG	32.2%	67.8%
	18099	220	coding	66.8%	33.2%
	18100	221	3'-UTR	67.2%	32.8%
	18101	222	coding	88.9%	11.1%
10	18102	223	stop	33.8%	66.2%
	18103	224	coding	30.2%	69.8%

**Example 16: Effect of B7 Antisense Oligonucleotides on Cell Surface Expression**

15        B7 antisense oligonucleotides were tested for their effect on cell surface expression of both B7-1 and B7-2. Cell surface expression was measured as described in Example 2. Experiments were done for both human B7 and mouse B7. Results for human B7 are shown in Table 16. Results for mouse B7 are 20 shown in Table 17.

      In both species, B7-1 antisense oligonucleotides were able to specifically reduce the cell surface expression of B7-1. B7-2 antisense oligonucleotides were specific for the B7-2 family member. These oligonucleotides were also specific for 25 their effect on B7-1 and B7-2 mRNA levels.

-91-

TABLE 16

Inhibition of Human B7 Cell Surface Expression by Chimeric  
(deoxy gapped) Phosphorothioate Oligodeoxynucleotides

	ISIS No:	SEQ ID NO:	GENE TARGET	% B7-1 EXPRESSION	% B7-2 EXPRESSION
5	basal	---	---	100%	0%
10	22316	26	B7-1	31%	100%
15	22317	129	B7-1	28%	91%
20	22320	132	B7-1	37%	86%
25	22324	135	B7-1	37%	91%
	22325	136	B7-1	32%	89%
	22334	145	B7-1	28%	92%
	22335	146	B7-1	23%	95%
	22337	148	B7-1	48%	101%
	22338	36	B7-1	22%	96%
	22284	16	B7-2	88%	32%
	22287	177	B7-2	92%	35%
	22294	184	B7-2	77%	28%

20

TABLE 17

Inhibition of Mouse B7 Cell Surface Expression by Chimeric  
(deoxy gapped) Phosphorothioate Oligodeoxynucleotides

	ISIS No:	SEQ ID NO:	GENE TARGET REGION	% B7-1 EXPRESSION	% B7-2 EXPRESSION
25	basal	---	---	100%	0%

-92-

18089	211	B7-2	85%	36%
18097	219	B7-2	87%	28%
18110	161	B7-1	31%	93%
18113	164	B7-1	25%	91%
5 18119	170	B7-1	27%	98%

Dose response experiments were performed on several of the more active human B7-1 antisense oligonucleotides. The oligonucleotides were screened as described in Example 2 except that the concentration of oligonucleotide was varied 10 as shown in Table 18. Results are shown in Table 18.

All antisense oligonucleotides tested showed a dose response effect with inhibition of cell surface expression approximately 60% or greater.

TABLE 18

## 15 Dose Response of COS-7 Cells to B7-1

## Chimeric (deoxy gapped) Antisense Oligonucleotides

ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% Surface Expression	% Surface Inhibition
basal	---	---	---	100%	---
20 22316	26	5'-UTR	10 nM	74%	26%
"	"	"	30 nM	74%	26%
"	"	"	100 nM	47%	53%
"	"	"	300 nM	34%	66%
22335	146	3'-UTR	10 nM	81%	19%
25 "	"	"	30 nM	69%	31%
"	"	"	100 nM	47%	53%
"	"	"	300 nM	38%	62%
22338	36	3'-UTR	10 nM	78%	22%

-91-

TABLE 16

Inhibition of Human B7 Cell Surface Expression by Chimeric  
(deoxy gapped) Phosphorothioate Oligodeoxynucleotides

	ISIS No:	SEQ ID NO:	GENE TARGET	% B7-1 EXPRESSION	% B7-2 EXPRESSION
5	basal	---	---	100%	0%
10	22316	26	B7-1	31%	100%
15	22317	129	B7-1	28%	91%
20	22320	132	B7-1	37%	86%
25	22324	135	B7-1	37%	91%
	22325	136	B7-1	32%	89%
	22334	145	B7-1	28%	92%
	22335	146	B7-1	23%	95%
	22337	148	B7-1	48%	101%
	22338	36	B7-1	22%	96%
	22284	16	B7-2	88%	32%
	22287	177	B7-2	92%	35%
	22294	184	B7-2	77%	28%

20

TABLE 17

Inhibition of Mouse B7 Cell Surface Expression by Chimeric  
(deoxy gapped) Phosphorothioate Oligodeoxynucleotides

	ISIS No:	SEQ ID NO:	GENE TARGET REGION	% B7-1 EXPRESSION	% B7-2 EXPRESSION
25	basal	---	---	100%	0%

-92-

18089	211	B7-2	85%	36%
18097	219	B7-2	87%	28%
18110	161	B7-1	31%	93%
18113	164	B7-1	25%	91%
5 18119	170	B7-1	27%	98%

Dose response experiments were performed on several of the more active human B7-1 antisense oligonucleotides. The oligonucleotides were screened as described in Example 2 except that the concentration of oligonucleotide was varied 10 as shown in Table 18. Results are shown in Table 18.

All antisense oligonucleotides tested showed a dose response effect with inhibition of cell surface expression approximately 60% or greater.

TABLE 18

## 15 Dose Response of COS-7 Cells to B7-1

## Chimeric (deoxy gapped) Antisense Oligonucleotides

ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% Surface Expression	% Surface Inhibition
basal	---	---	---	100%	---
20 22316	26	5'-UTR	10 nM	74%	26%
"	"	"	30 nM	74%	26%
"	"	"	100 nM	47%	53%
"	"	"	300 nM	34%	66%
22335	146	3'-UTR	10 nM	81%	19%
25 "	"	"	30 nM	69%	31%
"	"	"	100 nM	47%	53%
"	"	"	300 nM	38%	62%
22338	36	3'-UTR	10 nM	78%	22%

- 93 -

"	"	"	30 nM	65%	35%
"	"	"	100 nM	50%	50%
"	"	"	300 nM	40%	60%

5 Dose response experiments were performed on several of the more active human B7-2 antisense oligonucleotides. The oligonucleotides were screened as described in Example 2 except that the concentration of oligonucleotide was varied as shown in Table 19. Results are shown in Table 19.

10 All antisense oligonucleotides tested showed a dose response effect with maximum inhibition of cell surface expression 85% or greater.

TABLE 19

## Dose Response of COS-7 Cells to B7-2

15 Chimeric (deoxy gapped) Antisense Oligonucleotides

ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% Surface Expression	% Surface Inhibition
basal	---	---	---	100%	---
22284	16	5'-UTR	10 nM	63%	37%
"	"	"	30 nM	60%	40%
"	"	"	100 nM	37%	63%
"	"	"	300 nM	15%	85%
22287	177	AUG	10 nM	93%	7%
"	"	"	30 nM	60%	40%
"	"	"	100 nM	32%	68%
"	"	"	300 nM	15%	85%
22294	184	coding	10 nM	89%	11%
"	"	"	30 nM	62%	38%

- 94 -

"	"	"	100 nM	29%	71%
"	"	"	300 nM	12%	88%

**EXAMPLE 17: Effect of B7-1 Antisense Oligonucleotides in a  
5 Murine Model for Rheumatoid Arthritis**

Collagen-induced arthritis (CIA) was used as a murine model for arthritis (Mussener,A., et al., *Clin. Exp. Immunol.*, 1997, 107, 485-493). Female DBA/1LacJ mice (Jackson Laboratories, Bar Harbor, ME) between the ages of 10 6 and 8 weeks were used to assess the activity of B7-1 antisense oligonucleotides.

On day 0, the mice were immunized at the base of the tail with 100 µg of bovine type II collagen which is emulsified in Complete Freund's Adjuvant (CFA). On day 7, 15 a second booster dose of collagen was administered by the same route. On day 14, the mice were injected subcutaneously with 100 µg of LPS. Oligonucleotide was administered intraperitoneally daily (10 mg/kg bolus) starting on day -3 (three days before day 0) and continuing 20 for the duration of the study. Oligonucleotide 17456 (SEQ ID NO. 173) is a fully phosphorothioated analog of 18122.

Weights were recorded weekly. Mice were inspected daily for the onset of CIA. Paw widths are rear ankle widths of affected and unaffected joints were measured 25 three times a week using a constant tension caliper. Limbs were clinically evaluated and graded on a scale from 0-4 (with 4 being the highest).

Results are shown in Table 20. Treatment with B7-1 and B7-2 antisense oligonucleotides was able to reduce the 30 incidence of the disease, but had modest effects on severity. The combination of 17456 (SEQ ID NO. 173) and 11696 (SEQ ID NO. 108) was able to significantly reduce the incidence of the disease and its severity.

Table 20: Effect of B7 antisense oligonucleotide on CIA

ISIS #(s)	SEQ ID NO	Dose mg/kg	% Inci-dence	Peak day <sup>1</sup>	Severity <sup>2</sup>
control		---	70%	6.7 ± 2.9	3.2 ± 1.1
17456 (B7-1)	173	10	50%	12.1 ± 4.6	2.7 ± 1.3
5 11696 (B7-2)	108	10	37.5%	11.6 ± 4.5	3.4 ± 1.8
17456/11696		10	30%	1.0 ± 0.6	0.7 ± 0.4
18110 (B7-1)	161	10	55.6%	2.0 ± 0.8	2.0 ± 1.3
18089 (B7-2)	211	10	44.4%	6.8 ± 2.2	2.3 ± 1.3
10 18110/18089		10	60%	11.6 ± 0.7	4.5 ± 1.7

10

<sup>1</sup>Peak day is the day from onset of maximum swelling for each joint measure.

<sup>2</sup>Severity is the total clinical score divided by the total number of mice in the group.

15 EXAMPLE 18: Effect of B7-1 Antisense Oligonucleotides in a Murine Model for Multiple Sclerosis

Experimental autoimmune encephalomyelitis (EAE) is a commonly accepted murine model for multiple sclerosis (Myers, K.J., et al., *J. Neuroimmunol.*, 1992, 41, 1-8).

20 SJL/H, PL/J, (SJLxPL/J)F1, (SJLxBalb/c)F1 and Balb/c female mice between the ages of 6 and 12 weeks are used to test the activity of a B7-1 antisense oligonucleotide.

The mice are immunized in the two rear foot pads and base of the tail with an emulsion consisting of 25 encephalitogenic protein or peptide (according to Myers, K.J., et al., *J. of Immunol.*, 1993, 151, 2252-2260) in Complete Freund's Adjuvant supplemented with heat killed *Mycobacterium tuberculosis*. Two days later, the mice

-96-

receive an intravenous injection of 500 ng *Bordatella pertussis* toxin and additional adjuvant.

Alternatively, the disease may also be induced by the adoptive transfer of T-cells. T-cells are obtained from 5 the draining of the lymph nodes of mice immunized with encephalitogenic protein or peptide in CFA. The T cells are grown in tissue culture for several days and then injected intravenously into naive syngeneic recipients.

Mice are monitored and scored daily on a 0-5 scale for 10 signals of the disease, including loss of tail muscle tone, wobbly gait, and various degrees of paralysis.

Oligonucleotide 17456 (SEQ ID NO. 173), a fully phosphorothioated analog of 18122, was compared to a saline control and a fully phosphorothioated oligonucleotide of 15 random sequence (Oligonucleotide 17460). Results of this experiment are shown in Figure 11.

As shown in Figure 11, for all doses of oligonucleotide 17456 tested, there is a protective effect, i.e. a reduction of disease severity. At 0.2 mg/kg, this 20 protective effect is greatly reduced after day 20, but at the higher doses tested, the protective effect remains throughout the course of the experiment (day 40). The control oligonucleotide gave results similar to that obtained with the saline control.

25 **EXAMPLE 19: Additional antisense oligonucleotides targeted to human B7-1**

Additional oligonucleotides targeting human B7-1 were synthesized. Oligonucleotides were synthesized as uniformly phosphorothioate chimeric oligonucleotides having 30 regions of five 2'-O-methoxyethyl (2'-MOE) nucleotides at the wings and a central region of ten deoxynucleotides. Oligonucleotide sequences are shown in Table 21.

The human promonocytic leukaemia cell line, THP-1 (American Type Culture Collection, Manassas, VA) was

-97-

maintained in RPMI 1640 growth media supplemented with 10% fetal calf serum (FCS; Life Technologies, Rockville, MD). A total of  $1 \times 10^7$  cells were electroporated at an oligonucleotide concentration of 10 micromolar in 2 mm 5 cuvettes, using an Electrocell Manipulator 600 instrument (Biotechnologies and Experimental Research, Inc.) employing 200 V, 1000  $\mu$ F. Electroporated cells were then transferred to petri dishes and allowed to recover for 16 hrs. Cells were then induced with LPS at a final concentration of 1 10  $\mu$ g/ml for 16 hours. RNA was isolated and processed as described in previous examples. Results are shown in Table 22.

Oligonucleotides 113492, 113495, 113498, 113499, 113501, 113502, 113504, 113505, 113507, 113510, 113511, 15 113513 and 113514 (SEQ ID NO: 228, 231, 234, 235, 237, 238, 240, 241, 243, 247, 248, 250 and 251) resulted in 50% or greater inhibition of B7-1 mRNA expression in this assay.

TABLE 21:

20 Nucleotide Sequences of Human B7-1 Chimeric (deoxy gapped) Oligodeoxynucleotides

ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO.	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
113489	CCCTCCAGTGATGTTACAA	225	179	5' UTR
113490	GAAGACCCCTCCAGTGATGTT	226	184	5' UTR
25 113491	CGTAGAAGACCCCTCCAGTGA	227	188	5' UTR
113492	TTCCCAAGGTGCAAAACAGGC	228	234	5' UTR
113493	TGGCTTCAGATGCTTAGGGT	229	299	5' UTR
113494	CCTCCGTGTGGCCCATGG	230	316	AUG
113495	GGTGATGTTCCCTGCCTCCG	231	330	Coding

- 98 -

	113496	GATGGTGATGTTCCCTGCCT	232	333	Coding
	113497	AGGTATGGACACTTGGATGG	233	348	Coding
	113498	GAAAGACCAGCCAGCACCAA	234	384	Coding
	113499	CAGCGTTGCCACTTCTTC	235	442	Coding
5	113500	GTGACCACAGGACAGCGTTG	236	454	Coding
	113501	AGATGCGAGTTGTGCCAGC	237	491	Coding
	113502	CCTTTGCCAGTAGATGCGA	238	503	Coding
	113503	CGGTTCTTGTACTCGGGCCA	239	567	Coding
	113504	CGCAGAGCCAGGATCACAA	240	618	Coding
10	113505	CTTCAGCCAGGTGTTCCCGC	241	698	Coding
	113506	TAACGTCACCCAGCCAGGT	242	706	Coding
	113507	TTCTCCATTTCACCCAGG	243	838	Coding
	113508	CTGTTGTGTTGATGGCATT	245	863	Coding
	113509	CATGAAGCTGTGGTTGGTTG	246	943	Coding
15	113510	AGGAAAATGCTCTGCTTGG	247	1018	Coding
	113511	TGGGAGCAGGTTATCAGGAA	248	1033	Coding
	113512	TAAGGTAATGGCCCAGGATG	249	1051	Coding
	113513	GGTCAGGCAGCATATCACAA	250	1090	Coding
	113514	GCCCCTGCTTCTGCGGGACA	251	1188	3' UTR
20	113515	AGATCTTTCAGCCCCCTTGC	252	1199	3' UTR
	113516	TTTGTAAAGGGAGAATGCC	253	1271	3' UTR
	113517	AAAGGAGAGGGATGCCAGCC	254	1362	3' UTR
	113518	CAAGACAATTCAAGATGGCA	255	1436	3' UTR

25 <sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues (others are 2'-deoxy-). All 2'-methoxyethyl cytosines and 2'-deoxy

- 99 -

cytosines residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

<sup>2</sup>Co-ordinates from Genbank Accession No. M27533 to which the oligonucleotides are targeted.

5

TABLE 22

Inhibition of Human B7-1 mRNA Expression by Chimeric (deoxy gapped) Phosphorothioate Oligodeoxynucleotides

	ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
10	113489	225	5' UTR	122	--
	113490	226	5' UTR	183	--
	113491	227	5' UTR	179	--
	113492	228	5' UTR	27	73
	113493	229	5' UTR	488	--
	113494	230	AUG	77	23
15	113495	231	Coding	43	57
	113496	232	Coding	71	29
	113497	233	Coding	78	22
	113498	234	Coding	37	63
	113499	235	Coding	25	75
	113500	236	Coding	83	17
20	113501	237	Coding	36	64
	113502	238	Coding	26	74
	113503	239	Coding	65	35
	113504	240	Coding	46	54
	113505	241	Coding	40	60
	113506	242	Coding	105	--

-100-

	113507	243	Coding	36	64
	113508	245	Coding	117	--
	113509	246	Coding	62	38
	113510	247	Coding	43	57
5	113511	248	Coding	48	52
	113512	249	Coding	73	27
	113513	250	Coding	48	52
	113514	251	3' UTR	35	65
	113515	252	3' UTR	184	--
	113516	253	3' UTR	83	17
	113517	254	3' UTR	201	--
	113518	255	3' UTR	97	03

EXAMPLE 20: Additional antisense oligonucleotides targeted  
15 to human B7-2

Additional oligonucleotides targeting human B7-2 were synthesized. Oligonucleotides were synthesized as uniformly phosphorothioate chimeric oligonucleotides having regions of five 2'-O-methoxyethyl (2'-MOE) nucleotides at 20 the wings and a central region of ten deoxynucleotides. Oligonucleotide sequences are shown in Table 23.

The human promonocytic leukaemia cell line, THP-1 (American Type Culture Collection, Manassas, VA) was maintained in RPMI 1640 growth media supplemented with 10% 25 fetal calf serum (FCS; Life Technologies, Rockville, MD). A total of  $1 \times 10^7$  cells were electroporated at an oligonucleotide concentration of 10 micromolar in 2 mm cuvettes, using an Electrocell Manipulator 600 instrument (Biotechnologies and Experimental Research, Inc.) employing 30 200 V, 1000  $\mu$ F. Electroporated cells were then transferred

-101-

to petri dishes and allowed to recover for 16 hrs Cells were then induced with LPS and dibutyryl cAMP (500  $\mu$ M) for 16 hours. RNA was isolated and processed as described in previous examples. Results are shown in Table 24.

5 Oligonucleotides ISIS 113131, 113132, 113134, 113138, 113142, 113144, 113145, 113146, 113147, 113148, 113149, 113150, 113153, 113155, 113157, 113158, 113159 and 113160 (SEQ ID NO: 256, 257, 259, 263, 267, 269, 270, 271, 272, 273, 274, 275, 278, 280, 282, 283, 284 and 285) resulted in 10 50% or greater inhibition of B7-2 mRNA expression in this assay.

TABLE 23:

Nucleotide Sequences of Human B7-2 Chimeric (deoxy gapped) Oligodeoxynucleotides

15	ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
	113131	CGTGTGTCTGTGCTAGTCCC	256	38	5' UTR
	113132	GCTGCTTCTGCTGTGACCTA	257	83	5' UTR
20	113133	TATTTGCGAGCTCCCCGTAC	258	15	5' UTR
	113134	GCATAAGCACAGCAGCATT	259	79	5' UTR
	113135	TCCAAAAAGAGACCAGATGC	260	97	5' UTR
	113136	AAATGCCTGTCCACTGTAGC	261	117	5' UTR
	113137	CTTCAGAGGAGCAGCACCAG	262	191	Coding
25	113138	GAATCTTCAGAGGAGCAGCA	263	195	Coding
	113139	CAAATTGGCATGGCAGGTCT	264	237	Coding
	113140	GCTTGGTTTGAGAGTTG	265	257	Coding
	113141	AGGCTTGGTTTGAGAGTT	266	259	Coding

113142	GCTCACTCAGGCTTGGTTT	267	267	Coding	
113143	GGTCCTGCCAAAATACTACT	268	288	Coding	
113144	AGCCCTTGTCCCTGATCTGA	269	429	Coding	
113145	TGTGGGCTTTGTGATGGA	270	464	Coding	
5	113146	AATCATTCTGTGGGCTTT	271	473	Coding
	113147	CCGTGTATAGATGAGCAGGT	272	595	Coding
	113148	ACCGTGTATAGATGAGCAGG	273	596	Coding
	113149	TCATCTTCTTAGGTTCTGGG	274	618	Coding
	113150	ACAAGCTGATGGAAACGTCG	275	720	Coding
	113151	TGCTCGTAACATCAGGGAAT	276	747	Coding
10	113152	AAGATGGTCATATTGCTCGT	277	760	Coding
	113153	CGCGTCTTGTCAAGTTCCAG	278	787	Coding
	113154	CAGCTGTAATCCAAGGAATG	279	864	Coding
	113155	GGGCTTCATCAGATCTTC	280	1041	Coding
	113156	CATGTATCACTTTGTCGCA	281	1093	Coding
15	113157	AGCCCCCTTATTACTCATGG	282	1221	3' UTR
	113158	GGAGTTACAGGGAGGCTATT	283	1261	3' UTR
	113159	AGTCTCCTCTGGCATAACGG	284	1290	3' UTR
	113160	CCCATAAGTGTGCTCTGAAG	285	1335	3' UTR

20

<sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues (others are 2'-deoxy-). All 2'-methoxyethyl cytosines and 2'-deoxy cytosines residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

25

<sup>2</sup>For ISIS# 113131 and 113132, co-ordinates are from Genbank Accession No. L25259, locus name "HUMB72A". For remaining

-103-

oligonucleotides, co-ordinates are from Genbank Accession No.U04343, locus name "HSU04343".

TABLE 24

5 Inhibition of Human B7-2 mRNA Expression by Chimeric (deoxy  
gapped) Phosphorothioate Oligodeoxynucleotides

ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
113131	256	5' UTR	13	87
113132	257	5' UTR	17	83
10 113133	258	5' UTR	214	--
113134	259	5' UTR	27	73
113135	260	5' UTR	66	34
113136	261	5' UTR	81	19
113137	262	Coding	57	43
15 113138	263	Coding	12	88
113140	265	Coding	214	--
113141	266	Coding	126	--
113142	267	Coding	35	65
113143	268	Coding	118	--
20 113144	269	Coding	41	59
113145	270	Coding	46	54
113146	271	Coding	32	68
113147	272	Coding	35	65
25 113148	273	Coding	23	77
113149	274	Coding	29	71
113150	275	Coding	19	81

-104-

	113151	276	Coding	208	--
	113152	277	Coding	89	11
	113153	278	Coding	19	81
	113154	279	Coding	63	37
5	113155	280	Coding	13	87
	113156	281	Coding	83	17
	113157	282	3' UTR	13	87
	113158	283	3' UTR	20	80
	113159	284	3' UTR	43	57
10	113160	285	3' UTR	09	91

**EXAMPLE 21: Human skin psoriasis model**

Animal models of psoriasis based on xenotransplantation of human skin from psoriatic patients 15 are advantageous because they involve the direct study of affected human tissue. Psoriasis is solely a disease of the skin and consequently, engraftment of human psoriatic skin onto SCID mice allows psoriasis to be created with a high degree of fidelity in mice. One such model is that of Dam 20 et al., *J. Invest. Dermatol.*, 1999, 113, 1082-1089.

Briefly, keratome biopsies containing both dermis and epidermis are obtained from either clinically symptomless skin of psoriatic patients, or from psoriatic plaques. The keratomes are transferred to Earle's balanced Salt Solution 25 (GIBCO, Grand Island, NY) supplemented with 400 U penicillin/ml, 400 ug streptomycin/ml, and 4 mg gentamicin/ml, and stored at 4°C. Immediately before orthotopic transplantation onto the flank of 6-8 week old anesthetized C.B-17 SCID mice (Taconic Farms, Germantown, 30 NY), human skin xenografts (1.7 x 2.2 x 0.05 cm) are cut from the keratomes, and the grafts are secured to each SCID

-105-

mouse with absorbable sutures and covered with dressings for 1 wk. Animals are randomized into treatment groups and test compound (in this case the human B7-1 oligonucleotide ISIS 113492 or the human B7-2 oligonucleotide ISIS 113131, 5 or a combination of both oligonucleotides) is injected intradermally into the xenografts using a 30G needle. Within 3-4 weeks the animals are sacrificed and 4 mm punch biopsies are taken from each xenograft. Biopsies are fixed in formalin for paraffin embedding and/or transferred to 10 cryotubes and snap-frozen in liquid nitrogen and stored at -80°C.

What is claimed is:

1. A compound comprising 8 to 30 nucleotides connected by covalent linkages, wherein said oligonucleotide has a sequence specifically hybridizable with a nucleic acid encoding a B7 protein and said compound modulates the expression of said B7 protein.
2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 1, wherein at least one of said covalent linkages is a modified covalent linkage.
4. The compound of claim 1, wherein at least one of said nucleotides has a modified sugar moiety.
5. The compound of claim 4, wherein said modified sugar moiety is a modification at the 2' position of any nucleotide, the 3' position of the 3' terminal nucleotide or the 5' position of the 5' terminal oligonucleotide.
6. The compound of claim 1, wherein at least one of said nucleotides has a modified nucleobase.
7. The compound of claim 1 wherein said oligonucleotide comprises at least one lipophilic moiety which enhances the cellular uptake of said oligonucleotide.
8. The compound of claim 1 wherein said B7 protein is human B7-1.
9. The compound of claim 8 wherein said sequence comprises SEQ ID NO: 228, 231, 234, 235, 237, 238, 240, 241, 243, 247, 248, 250 or 251.
10. The compound of claim 1 wherein said B7 protein is human B7-2.
11. The compound of claim 10 wherein said sequence comprises SEQ ID NO: 256, 257, 259, 263, 267, 269, 270, 271, 272, 273, 274, 275, 278, 280, 282, 283, 284 or 285.

-107-

12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

13. The composition of claim 12 further comprising an anti-inflammatory or immunosuppressive agent.

5 14. A composition comprising

- (a) the compound of claim 8;
- (b) the compound of claim 10 and
- (c) a pharmaceutically acceptable carrier.

15. The composition of claim 14 further comprising an 10 anti-inflammatory or immunosuppressive agent.

16. A method of modulating the expression of a B7 protein in cells or tissues comprising contacting said cells or tissues with a compound of claim 1.

17. The method of claim 16 wherein said cells or 15 tissues are antigen presenting cells.

18. A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a compound of claim 1.

20 19. The method of claim 18 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.

25 20. A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a composition of claim 12.

21. The method of claim 20 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.

---

30 22. A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a composition of claim 14.

-108-

23. The method of claim 22 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.

24. A method of inhibiting a T cell response in 5 antigen-presenting cells comprising contacting antigen presenting cells with a compound of claim 1.

25. A method of inhibiting allograft rejection in an animal comprising administering to said animal a compound of claim 1.


10 26. A method of inhibiting allograft rejection in an animal comprising administering to an animal an anti-inflammatory or immunosuppressive agent and a compound of claim 1.

15 27. A method of inhibiting allograft rejection in an animal comprising administering to the animal the composition of claim 12.

28. The method of claim 27 further comprising administering to the animal an anti-inflammatory or immunosuppressive agent.

20 29. A method of inhibiting allograft rejection in an animal comprising administering to the animal the composition of claim 14.


30. The method of claim 29 further comprising administering to the animal an anti-inflammatory or 25 immunosuppressive agent.



**Fig. 1**




2/10



***Fig. 2***




3/10



**Fig. 3**




4/10



*Fig. 4*



5/10





6/10





Fig. 6



7/10





8/10




Fig. 8



9/10




Fig. 9



10/10




Fig. 10



## SEQUENCE LISTING

<110> Bennett, Clarence Frank  
Vickers, Timothy A.  
Karras, James G.  
ISIS PHARMACEUTICALS, INC.

<120> Oligonucleotide Compositions and Methods for the  
Modulation of the Expression of B7 Protein

<130> ISPH-0459

<150> 09/326,186  
<151> 1999-06-04

<150> 08/777,266  
<151> 1996-12-31

<160> 224

<170> PatentIn Ver. 2.0

<210> 1  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 1  
gatcagggta ccaggagcct taggaggtac gg 32

<210> 2  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 2  
gatagcctcg agttatttcc aggtcatgag cca 33

<210> 3  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 3  
ttccaggtca tgagccatTA 20

---

<210> 4  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 4  
cataaggtgt gctctgaagt g 21  
<210> 5  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 5  
ttactcatgg taatgtcttt 20  
<210> 6  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 6  
attaaaaaaca tgtatcactt 20  
<210> 7  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 7  
ggaacacaga agcaaggagg t 21  
<210> 8  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 8  
ccgtacacctcc taaggctcct 20  
<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic

---

<400> 9  
cccatatgtgc tgtcacaaat 20  
<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 10  
gcacagcagc attcccaagg 20

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 11  
ttgcaaattg gcatggcagg 20

<210> 12  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 12  
tggtatggc tttactctt 20

<210> 13  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 13  
aaaaggttgc ccaggaacgg 20

<210> 14  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 14  
gggagtccctg gagccccctt 20

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 15  
ccatTAAGCT gggCTTGGCC 20

<210> 16  
<211> 20



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 16  
tgcgagctcc ccgtacctcc

20

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<300>  
<310> US 5514788  
<311> 1993-05-17  
<312> 1996-05-07

<400> 17  
gccccaaagctg gcatccgtca

20

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 18  
ggattgccaa gcccatggtg

20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 19  
ctaagtagtg ctagccggga

20

<210> 20  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 20  
gatcagggtta ccccaaagaa aaagtgattt gtcattgc

38

<210> 21  
<211> 35  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 21  
gatagcctcg aggataatga attggctgac aagac 35

<210> 22  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 22  
gggttaagact ccacttctga 20

<210> 23  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 23  
gggtctccaa aggttgtgga 20

<210> 24  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 24  
gttcctgggt ctccaaaggt 20

<210> 25  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 25  
acacacagag attggagggt 20

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 26  
gctcacgtag aagaccctcc 20

<210> 27  
<211> 20



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 27  
ggcagggtcg atgacaatcc 20

<210> 28  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 28  
tgcaaaacag gcagggctga 20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 29  
agaccagggc acttcccagg 20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 30  
cctgcctccg tgtgtggccc 20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 31  
gaccagccag caccaagagc 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 32  
ccacaggaca gcgttgccac 20



<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 33  
ccgggttcttg tactcgggccc 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 34  
ccaaaccaggaa gaggtgaggc 20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 35  
ggcaaaggcag taggtcaggc 20

<210> 36  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 36  
gcctcatgat ccccacgatc 20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 37  
agtccctacta ccagccgcct 20

---

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 38  
tcagggttaag actccacttc 20  
<210> 39  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 39  
agggtgttcc tgggtctcca 20  
<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 40  
ctccgtgtgt ggcccatggc 20  
<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 41  
ggatgggtat gttccctgcc 20  
<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 42  
tgagaaagac cagccagcac 20  
<210> 43  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 43  
gggcgcagag ccaggatcac 20  
<210> 44  
<211> 20  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 44  
ggcccaggat gggagcaggt 20

<210> 45  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 45  
agggcgtaca ctttcccttc 20

<210> 46  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 46  
cagcccccttg cttctgcgga 20

<210> 47  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 47  
aaggagaggg atgccagcca 20

<210> 48  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 48  
ctgttacttt acagagggtt tg 22

<210> 49  
<211> 25  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 49  
cttctgttac tttacagagg gtttg 25

<210> 50  
<211> 21



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 50  
ctgttacttt acagagggtt t

21

<210> 51  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 51  
gccctcgta gatgggcgca

20

<210> 52  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 52  
agtccctacta ccagccgcct

20

<210> 53  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 53  
agtaagagtc tattgaggtt

20

<210> 54  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 54  
ggttgagttt cacaacctga

20

<210> 55  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 55  
gtccacagaa tggaacagag

20



<210> 56  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 56  
ggcatccacc cggcagatgc

20

<210> 57  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 57  
tggatggcat ccacccggca

20

<210> 58  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 58  
aggcacctcc taggctcaca

20

<210> 59  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 59  
gccaatggag cttaggcacc

20

<210> 60  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 60  
catgatgggg aaagccagga

20

---

<210> 61  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 61  
aattgcaagc catagttca 20

<210> 62  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 62  
cgggcaaggca gcaatacctt 20

<210> 63  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 63  
cccgagcaatg acagacagca 20

<210> 64  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 64  
ggtcgtgaaag gaccaggccc 20

<210> 65  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 65  
tgggaaaccc ccgaaagcaa 20

<210> 66  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

---

<400> 66  
ggctttggga aaccccccggaa 20

<210> 67  
<211> 19  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 67  
tcagattcag gatctggga 19

<210> 68  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 68  
cccaggtgaa gtcctctgac 20

<210> 69  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 69  
ctgcgcgcaa tcctgcccc 20

<210> 70  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 70  
caggccgaa ggtaaggctg 20

<210> 71  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 71  
tcagctagca cggtgctgaa 20

<210> 72  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 72  
ggcccgacaa acttgcccg 20

<210> 73  
<211> 20



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 73  
ccaccacagt gggctcagcc 20

<210> 74  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 74  
ggccatgagg gcaatctaa 19

<210> 75  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 75  
gtggccatga gggcaatcta a 21

<210> 76  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 76  
gatttaacat ttggcgccca 20

<210> 77  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 77  
aaagttacaa cattatatct 20

---

<210> 78  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 78  
agtgcgattc tcaaacctac 20



<210> 79  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 79  
tatttgcgag ctcccc

16

<210> 80  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 80  
tatttgcgag ctcccc

15

<210> 81  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 81  
tatttgcgag ctcc

14

<210> 82  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 82  
cgacagctcc tgcgctcctc

20

<210> 83  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 83  
agctccccgt acctcc

16

---

<210> 84  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 84  
tgcgagctcc ccgtac 16

<210> 85  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 85  
ctcccccgtac 10

<210> 86  
<211> 11  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 86  
gctcccccgt a c 11

<210> 87  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 87  
agctcccccgt a c 12

<210> 88  
<211> 13  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 88  
gagctcccccgt a c 13

<210> 89  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 89  
cgagctcccc gtac 14

<210> 90  
<211> 15  
<212> DNA  
<213> Artificial Sequence



```

<220>
<223> Synthetic

<400> 90
gcgagctccc cgtac 15

<210> 91
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 91
gcgagctccc cgt 13

<210> 92
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 92
gccgcccggcca agtct 15

<210> 93
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 93
gagaagcaaa gcttcaccc tgtg 24

<210> 94
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 94
gaagcaaagc tttcacccctg tg 22

<210> 95
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 95
gcaaagctt caccctgtg 19

<210> 96
<211> 24

```



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 96  
ctccccgtac ctcctaaggc tcct

24

<210> 97  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 97  
ccccgtaccc ccttaaggctc ct

22

<210> 98  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 98  
ccgtacacctcc taaggctcc

19

<210> 99  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 99  
gatcagggtta ccaagagtgg ctcctgtagg ca

32

<210> 100  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 100  
gatagcctcg aggtagaatt ccaatcagct ga

32

<210> 101  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<300>  
<302> Blocking of Heart Allograft Rejection by Intercellular



Adhesion Molecule-1 Synthetic Alone or  
in Combination with Other Immunosuppressive Modalities

&lt;303&gt; J. Immunol.

&lt;304&gt; 153

&lt;306&gt; 5336-5346

&lt;307&gt; 1994-12-01

&lt;400&gt; 101

tgcatcccccc aggccaccat

20

&lt;210&gt; 102

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;300&gt;

<302> Blocking of Heart Allograft Rejection by Intercellular  
Adhesion Molecule-1 Synthetic Alone or  
in Combination with Other Immunosuppressive Modalities

&lt;303&gt; J. Immunol.

&lt;304&gt; 153

&lt;306&gt; 5336-5346

&lt;307&gt; 1994-12-01

&lt;400&gt; 102

gccgagggtcc atgtcgtacg c

21

&lt;210&gt; 103

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 103

acacgtctac aggagtctgg

20

&lt;210&gt; 104

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 104

caagcccatg gtgcacatctgg

20

&lt;210&gt; 105

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 105

ctgggggtcca tcgtgggtgc

20



<210> 106  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 106  
ccgtgctgcc tacaggagcc

20

<210> 107  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 107  
ggtgcttccg taagttctgg

20

<210> 108  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 108  
ggattgccaa gcccatggtg

20

<210> 109  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 109  
ctaagttagtg ctagccggga

20

<210> 110  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 110  
tgcgtctcca cgaaaaacagc

20

---

<210> 111  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 111  
gtgcggccca ggtacttggc 20

<210> 112  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 112  
acaaggagga gggccacagt 20

<210> 113  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 113  
tgagagggtt ggaggaaatc 20

<210> 114  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 114  
gatagtctct ctgtcagcgt 20

<210> 115  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 115  
gttgctgggc ctgctaggct 20

<210> 116  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

---

<400> 116  
ctaggtctcg tcgtcggtgg 20

<210> 117  
<211> 20  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 117  
tctcaactgcc ttcactctgc 20

<210> 118  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 118  
gtaccagatg aaggttatca a 21

<210> 119  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 119  
ctttggagat tattcgagtt 20

<210> 120  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 120  
gcaagtgtaa agccctgagt 20

<210> 121  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 121  
agaattccaa tcagctgaga 20

<210> 122  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 122  
tctgagaaac tctgcacttc 20

<210> 123  
<211> 20



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 123  
tcctcaggtt ctcactgcct 20

<210> 124  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 124  
ggttgttcaa gtccgtgctg 20

<210> 125  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 125  
gccgagggtcc atgtcgtagc c 21

<210> 126  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 126  
agactccact tctgagatgt 20

<210> 127  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 127  
tgaagaaaaa ttccactttt 20

<210> 128  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 128  
tttagtttca cagcttgctg 20



<210> 129  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 129  
tcccaggtgc aaaacaggca 20

<210> 130  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 130  
gtgaaaggcca acaatttggaa 20

<210> 131  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 131  
catggcttca gatgcttagg 20

<210> 132  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 132  
ttgaggtatg gacacttgga 20

<210> 133  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 133  
gcgttgcac ttctttcact 20

---

<210> 134  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 134  
ttttgccagt agatgcgagt 20  
<210> 135  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 135  
ggccatataat tcatgtcccc 20  
<210> 136  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 136  
gccaggatca caatggagag 20  
<210> 137  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 137  
gtatgtgccc tcgtcagatg 20  
<210> 138  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  
  
<400> 138  
ttcagccagg tggcccgct 20  
<210> 139  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic  

---

  
<400> 139  
ggaagtcagc tttgactgat' 20  
<210> 140  
<211> 20  
<212> DNA  
<213> Artificial Sequence



```
<220>
<223> Synthetic

<400> 140
cctccagagg ttgagcaaat 20

<210> 141
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 141
ccaaaccaggaa gaggtgaggc 20

<210> 142
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 142
gaagctgtgg ttgggtgtca 20

<210> 143
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 143
ttgaaggctt gattcactct 20

<210> 144
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 144
aaggtaatgg cccaggatgg 20

<210> 145
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 145
aaggcaggagg tcagggcagca 20

<210> 146
<211> 20
```



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 146  
ccttgcttct gcggacactg 20

<210> 147  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 147  
agcccccgtgc ttctgcggac 20

<210> 148  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 148  
tgacggaggc taccttcaga 20

<210> 149  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 149  
gtaaaacagc ttaaaatttgt 20

<210> 150  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 150  
agaagagggtt acattaagca 20

<210> 151  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 151  
agataatgaa ttggctgaca 20



<210> 152  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 152  
gcgtcatcat ccgcaccatc 20

<210> 153  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 153  
cgttgcttgt gccgacagtg 20

<210> 154  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 154  
gctcacgaag aacaccttcc 20

<210> 155  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 155  
agagaaaacta gtaagagtct 20

<210> 156  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 156  
tggcatccac ccggcagatg 20

---

<210> 157  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 157  
tcgagaaaaca gagatgtaga 20

<210> 158  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 158  
tggagcttag gcacccctca 20

<210> 159  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 159  
tggggaaagc caggaatcta 20

<210> 160  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 160  
cagcacaaag agaagaatga 20

<210> 161  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 161  
atgaggagag ttgttaacggc 20

<210> 162  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 162  
aagtcccggtt cttataactcg 20

<210> 163  
<211> 20  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 163  
gcaggttaatc ctttttagtgt 20

<210> 164  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 164  
gtgaagtctt ctgacacgtg 20

<210> 165  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 165  
cgaatccctgc cccaaagagc 20

<210> 166  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 166  
actgcgccga atcctgcccc 20

<210> 167  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 167  
ttgatgatga caacgatgac 20

<210> 168  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 168  
ctgttgttg tttctctgct 20

<210> 169  
<211> 20



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 169  
tgttcagcta atgcttcttc 20

<210> 170  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 170  
gttaactcta tcttgtgtca 20

<210> 171  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 171  
tccacttcag tcatcaagca 20

<210> 172  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 172  
tgctcaatac tctctttta 20

<210> 173  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 173  
aggcccagca aacttgcccg 20

<210> 174  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 174  
aacggcaagg cagcaatacc 20



<210> 175  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 175  
cagaagcaag gtggtaagaa 20

<210> 176  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 176  
gcctgtccac ttagctcca 20

<210> 177  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 177  
agaatgttac tcagtcacat 20

<210> 178  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 178  
tcagaggagc agcaccagag 20

<210> 179  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 179  
tggcatggca ggtctgcagt 20

---

<210> 180  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 180  
agctcactca ggctttggtt 20

<210> 181  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 181  
tgcctaaatgta tacctcattc 20

<210> 182  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 182  
ctgtcaaattt tctctttgcc 20

<210> 183  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 183  
catatacttg gaatgaacac 20

<210> 184  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 184  
ggtccaaactg tccgaatcaa 20

<210> 185  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

---

<400> 185  
tgatctgaag attgtgaagt 20

<210> 186  
<211> 20  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 186  
aagcccttgt ccttgatctg 20

<210> 187  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 187  
tgtgatggat gatacattga 20

<210> 188  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 188  
tcaggttac tgaagttac 20

<210> 189  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 189  
gtgtatagat gagcaggtca 20

<210> 190  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 190  
tctgtgacat tatcttgaga 20

<210> 191  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 191  
aagataaaag ccgcgtcttg 20

<210> 192  
<211> 20



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 192  
agaaaaccat cacacatata 20

<210> 193  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 193  
agagttgcga ggccgcgttct 20

<210> 194  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 194  
tccctctcca ttgtgttggt 20

<210> 195  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 195  
catcagatct ttcaggtata 20

<210> 196  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 196  
ggctttactc tttaattaaa 20

<210> 197  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 197  
gaaatcaaaa aggttgccca 20



<210> 198  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 198  
ggagtccctgg agccccctta

20

<210> 199  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 199  
ttggcatacgt gagcagagct

20

<210> 200  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 200  
tgtgctctga agtggaaaaga

20

<210> 201  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 201  
ggcttggccc ataagggtgc

20

<210> 202  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 202  
cctaaatttt atttccaggt

20

---

<210> 203  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic



<400> 203  
gctccaagtg tcccaatgaa 20

<210> 204  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 204  
agtatgttgc tcactccgat 20

<210> 205  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> control oligonucleotide

<400> 205  
tgccagcacc cggtagtcc 20

<210> 206  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 206  
gctgcctaca ggagccactc 20

<210> 207  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 207  
tcaagtccgt gctgcctaca 20

<210> 208  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

---

<400> 208  
gtctacagga gtctgggtgt 20

<210> 209  
<211> 20  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> Synthetic

<400> 209  
agcttgcgtc tccacggaaa 20

<210> 210  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 210  
tcacactatc aagtttctct 20

<210> 211  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 211  
gtcaaagctc gtgcggccca 20

<210> 212  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 212  
gtgaagtctgt agagtccagt 20

<210> 213  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 213  
gtgacacctgc ttagacgtgc 20

<210> 214  
<211> 20  
<212> DNA  
<213> Artificial Sequence

---

<220>  
<223> Synthetic

<400> 214  
catcttctta ggtttcgggt 20

<210> 215  
<211> 20



<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 215  
ggctgttgg a gatactgaac 20

<210> 216  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 216  
ggaaatgaaa gagagaggct 20

<210> 217  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 217  
acataacaatg atgagcagca 20

<210> 218  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 218  
gtctctctgt cagcgttact 20

<210> 219  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 219  
tgccaaaggccc atggtgcatc 20

<210> 220  
<211> 20  
<212> DNA

---

<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 220  
gcaatttggg gttcaagttc 20



<210> 221  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 221  
caatcagctg agaacatTTT

20

<210> 222  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 222  
ttttgtataa aacaatcata

20

<210> 223  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 223  
ccttcactct gcatttggTT

20

<210> 224  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 224  
tgcatgttat caccataactc


20



**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US00/14471

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : A61K 31/70; C07H 21/00; C12N 5/06 US CL : 435/375; 514/44; 536/24.5 According to International Patent Classification (IPC) or to both national classification and IPC																									
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91.31, 375; 514/44; 536/24.31, 24.5																									
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																									
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet																									
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 80%;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width: 10%;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>US 6,077,833 A (BENNETT et al.) 20 June 2000, see entire document.</td> <td>1-8, 10, and 12-30</td> </tr> <tr> <td>X</td> <td>US 5,942,607 A (FREEMAN et al.) 24 August 1999, see column 3, line 61, to column 4, line 15; column 14, lines 30-37; and column 17, line 59, to column 18, line 50, especially column 18, lines 34-50.</td> <td>1, 2, 8, 10, 12, 16-21, 24-28</td> </tr> <tr> <td>---</td> <td></td> <td>13-15, 22, 23, 29, and 30</td> </tr> <tr> <td>X</td> <td>US 5,877,021 A (STINCHCOMB et al.) 02 March 1999, see column 5, line 66, to column 6, line 23; column 7, line 26, to column 8, line 60; column 10, line 15 to column 12, line 45; and column 15, lines 36-37.</td> <td>1-5, 8, 10, and 12-30</td> </tr> <tr> <td>---</td> <td></td> <td>6, 7</td> </tr> <tr> <td>X</td> <td>US 5,667,998 A (DOUGHERTY et al.) 16 September 1997, see column 24, line 35, to column 27, line 27.</td> <td>1, 8, 10, 16, 17, 24, 27</td> </tr> <tr> <td>X</td> <td>WO 96/18736 (RIBOZYME PHARMACEUTICALS) 20 June 1996, see page 19, line 25, to page 20, line 2; page 33, line 10, to page 36, line 16; page 37, line 20, to page 41, line 4; and page 45, line 3, to page 56, line 26.</td> <td>1-6, 8, 10, and 12-30</td> </tr> </tbody> </table>		Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	A	US 6,077,833 A (BENNETT et al.) 20 June 2000, see entire document.	1-8, 10, and 12-30	X	US 5,942,607 A (FREEMAN et al.) 24 August 1999, see column 3, line 61, to column 4, line 15; column 14, lines 30-37; and column 17, line 59, to column 18, line 50, especially column 18, lines 34-50.	1, 2, 8, 10, 12, 16-21, 24-28	---		13-15, 22, 23, 29, and 30	X	US 5,877,021 A (STINCHCOMB et al.) 02 March 1999, see column 5, line 66, to column 6, line 23; column 7, line 26, to column 8, line 60; column 10, line 15 to column 12, line 45; and column 15, lines 36-37.	1-5, 8, 10, and 12-30	---		6, 7	X	US 5,667,998 A (DOUGHERTY et al.) 16 September 1997, see column 24, line 35, to column 27, line 27.	1, 8, 10, 16, 17, 24, 27	X	WO 96/18736 (RIBOZYME PHARMACEUTICALS) 20 June 1996, see page 19, line 25, to page 20, line 2; page 33, line 10, to page 36, line 16; page 37, line 20, to page 41, line 4; and page 45, line 3, to page 56, line 26.	1-6, 8, 10, and 12-30
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																							
A	US 6,077,833 A (BENNETT et al.) 20 June 2000, see entire document.	1-8, 10, and 12-30																							
X	US 5,942,607 A (FREEMAN et al.) 24 August 1999, see column 3, line 61, to column 4, line 15; column 14, lines 30-37; and column 17, line 59, to column 18, line 50, especially column 18, lines 34-50.	1, 2, 8, 10, 12, 16-21, 24-28																							
---		13-15, 22, 23, 29, and 30																							
X	US 5,877,021 A (STINCHCOMB et al.) 02 March 1999, see column 5, line 66, to column 6, line 23; column 7, line 26, to column 8, line 60; column 10, line 15 to column 12, line 45; and column 15, lines 36-37.	1-5, 8, 10, and 12-30																							
---		6, 7																							
X	US 5,667,998 A (DOUGHERTY et al.) 16 September 1997, see column 24, line 35, to column 27, line 27.	1, 8, 10, 16, 17, 24, 27																							
X	WO 96/18736 (RIBOZYME PHARMACEUTICALS) 20 June 1996, see page 19, line 25, to page 20, line 2; page 33, line 10, to page 36, line 16; page 37, line 20, to page 41, line 4; and page 45, line 3, to page 56, line 26.	1-6, 8, 10, and 12-30																							
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																									
Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier application or patent published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed																									
Date of the actual completion of the international search <input type="text" value="20 July 2000 (20.07.2000)"/> Date of mailing of the international search report <input type="text" value="14 AUG 2000"/>																									
Name and mailing address of the ISA/US Commission of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230																									
Authorized officer  Thomas G. Callinifer, Ph.D. Telephone No. (703) 308-0196																									

